
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

37029108
1409
10.1038/s41392-023-01409-4
Review Article
Cdc2-like kinases: structure, biological function and therapeutic targets for diseases
Song Mengqiu 123
http://orcid.org/0000-0002-8224-9250
Pang Luping 345
Zhang Mengmeng 14
Qu Yingzi 14
Laster Kyle Vaughn 2
http://orcid.org/0000-0002-4174-4028
Dong Zigang dongzg@zzu.edu.cn

1234
1 https://ror.org/04ypx8c21 grid.207374.5 0000 0001 2189 3846 Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan 450001 China
2 https://ror.org/02dknqs67 grid.506924.c China-US (Henan) Hormel Cancer Institute, No.127, Dongming Road, Jinshui District, Zhengzhou, Henan 450008 China
3 https://ror.org/04ypx8c21 grid.207374.5 0000 0001 2189 3846 State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan China
4 https://ror.org/04ypx8c21 grid.207374.5 0000 0001 2189 3846 Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan 450001 China
5 grid.207374.5 0000 0001 2189 3846 Research Center of Basic Medicine, Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan 450001 China
7 4 2023
7 4 2023
2023
8 1484 7 2022
15 3 2023
20 3 2023
© The Author(s) 2023
2023
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The CLKs (Cdc2-like kinases) belong to the dual-specificity protein kinase family and play crucial roles in regulating transcript splicing via the phosphorylation of SR proteins (SRSF1–12), catalyzing spliceosome molecular machinery, and modulating the activities or expression of non-splicing proteins. The dysregulation of these processes is linked with various diseases, including neurodegenerative diseases, Duchenne muscular dystrophy, inflammatory diseases, viral replication, and cancer. Thus, CLKs have been considered as potential therapeutic targets, and significant efforts have been exerted to discover potent CLKs inhibitors. In particular, clinical trials aiming to assess the activities of the small molecules Lorecivivint on knee Osteoarthritis patients, and Cirtuvivint and Silmitasertib in different advanced tumors have been investigated for therapeutic usage. In this review, we comprehensively documented the structure and biological functions of CLKs in various human diseases and summarized the significance of related inhibitors in therapeutics. Our discussion highlights the most recent CLKs research, paving the way for the clinical treatment of various human diseases.

Subject terms

Drug development
Oncogenes
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) NO. 8207112153 No. 82002620 Song Mengqiu Dong Zigang issue-copyright-statement© West China Hospital, Sichuan University 2023
==== Body
pmcIntroduction of CLKs

The Cdc2-like kinases (CLKs) belong to the dual-specificity protein kinase (DSK)family, which catalyze the phosphorylation of serine, threonine, and tyrosine of substrates.1 The CLKs family consists of four homologous proteins (CLK1 - 4) and all family members are evolutionarily conserved in eukaryots.2,3 Specifically, CLKs are classified as a CMGC kinase (cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAPKs), glycogen synthase kinases (GSKs), and CDK-like kinases) group that share the same ATP co-factor and catalyze the phosphorylation of downstream protein substrates.4–6 The CLK kinase domain contains an “EHLAMMERILG” motif and is located at the C-terminus of each family member. Thus, CLK proteins are also known as the “LAMMER” family7 (Fig. 1a). CLKs are located in the cytoplasm and nucleus, but mainly exert functions in the nuclear compartment by phosphorylating the serine / arginine (Ser-Arg) -rich domain of splicing factors.8–10 Generally, phosphorylation of CLKs downstream substrates is driven by recognition of the universal consensus R-x-x-S/T sequence.3,11 On this basis, CLKs control pre-mRNA splicing to generate different protein isoforms, which play crucial roles in cell growth and survival.11 SR proteins (SRSF1–12) are well-defined substrates of CLKs that bind with pre-mRNA and related spliceosome components to facilitate spliceosome assembly.12–14 Activated SR proteins that have been phosphorylated by CLKs participate in alternative splicing (AS) and catalyze splicing processes.12 On the contrary, the functional SR proteins are subsequently dephosphorylated by phosphatases. This process is required for the export of spliced mRNA from the nucleus.12,15,16Fig. 1 Structural comparison of human CLKs. a Domain structures of human CLK1, -2, -3, and -4. b Crystal structure of human CLK1 without N-terminus domain (PDB ID: 6I5H). The protein structure backbone is visualized as a cartoon representation, while the ligand and its interacting residues are visualized as sticks. H-bonds are shown as black dashed lines. The coloring of all domains and signature sequence motifs are consistent with panel a. c Structural superposition of CLK1 (PDB ID: 6I5H, green), CLK2 (PDB ID: 6KHE, cyan), CLK3 (PDB ID: 2EU9, magenta) and CLK4 (PDB ID: 6FYV, yellow). The protein structural backbone is represented as a ribbon. d Electrostatic surface representation of CLKs. The blue and red colors represent positive and negative charges, respectively. The different pockets among these kinases were determined by the distances between side chains of conserved Val residue in the N-lobe and DFG-1 residue in the C-lobe

Among the four family members of CLKs, CLK1 has been structurally and functionally well characterized. CLK1, also termed STY, has been identified to be auto-phosphorylated at Ser / Thr / Tyr residues and phosphorylates Ser residues of its substrates.17,18 The catalytic domain of CLK1 is located at the C-terminus, whereas the N-terminus contains the Ser-Arg repeats responsible for mediating the interactions with the corresponding substrates.9 The kinase domain of CLK1 phosphorylates not only Ser-Arg dipeptide, but also Ser-Lys and Ser-Pro sites.19 Functionally, CLK1 is co-localized with SR proteins in the nucleus and facilitates the conformational change of the SRSF1 protein. This process subsequently disrupts the export of SRSF1 from the nucleus to cytosol and heightens SRSF1 binding to primary transcripts.20 However, loss of SRSF1 phosphorylation results in decreased alternative splicing of more than 100 genes, leading to irregular gene expression.20,21 CLK1 abundance was shown to vary periodically over the cell cycle and reached a peak at the G2/M phase, indicating a close relationship between CLK1 expression and cell cycle progression.21 Similar to CLK1, CLK2, −3, and −4 were also shown to contribute to cell growth and disease occurrence via the regulation of splicing.12 In addition, human CLK2 was found to play a role in fatty liver disease through participating in fatty acid oxidation and ketogenesis.22 CLK3 was suggested to play a pivotal role in the fertilization process due to its overexpression in mature spermatozoa.23 CLK4 has been implicated to modulate pre-mRNA intron-retaining splicing after stress withdraw.12,24 Collectively, CLKs act as critical regulators and exert important functions which are essential in catalyzing splicing and modulating phosphorylation. In this review, we systematically describe the structure of CLK family members, their biological functions, and the potential roles in human diseases progression, such as neurodegenerative diseases, inflammatory diseases, viral replication, and cancer. Finally, we comprehensively summarize the related small molecular inhibitors of CLKs and their therapeutic potential in various human diseases.

Crystal structure of CLKs

Structurally, all four members of the human CLKs share highly conserved topology. Each of the proteins is comprised of a flexible unstructured N-terminal region (around 140–300 residues) and a conserved kinase domain3,7 (Fig. 1a). Despite being unstructured, the N-terminal extensions of CLKs were reported to resemble similar RS (arginine / serine) domains present in their target SR protein substrates which then act as a bridge mediating the interactions between their kinase domain and the RS domain of the SR proteins. Removing this N-terminus of CLK1 results in a significant decrease of the phosphorylation level of the RS domain of SRSF1. This observation further reflects that the intrinsic disordered region of CLK1 and its mediated protein-protein contacts not only enhances the binding of the downstream proteins but also facilitates the hyperphosphorylation of the substrates.25

In contrast, the catalytic domain of CLKs is well-ordered and displays a typical kinase fold, containing an N-lobe and a C-lobe bridged by a hinge region forming a conserved ATP binding pocket3,12 (Fig. 1). The N-lobe consists of three β-strands, an α-helix, and two additional β-strands. The C-lobe possesses three conserved structural insertions defining the CLK family.3 These signature motifs are β-hairpin insertion, a LAMMER domain, and a mitogen-activated protein kinase (MAPK)-like insertion (Fig. 1). The extended β-hairpin insertion present at the top of the C-lobe (residues 297–319 in CLK1, 299–321 in CLK2, 440–462 in CLK3 and 295–317 in CLK4) is highly conserved in CLK family members. Another predominant sequence motif has invariant “EHLAMMERILG” region (residues 386–396 in CLK1, 388–398 in CLK2, 529–539 in CLK3 and 384–394 in CLK4), from which the family name LAMMER protein kinase is derived, located at the bottom of the C-lobe (Fig. 1). The last shared MAPK-like insertion is organized as helix-strand-strand-helix while in the same region in MAPK protein family, the two-strand β-sheet is substituted with a loop. These structural features of CLK-specific sequence motifs are likely important for their substrate recognition and binding specificity.

Structural superimposition of all human CLKs protein crystal structures demonstrated that their kinase domains share very similar topological features3,26,27 (Fig. 1c). Thus, CLK inhibitors are typically ATP mimetics that exert their activity through binding within the ATP pocket. As shown in Fig. 1b, the inhibitor generally contains aromatic heterocycles which are sandwiched between hydrophobic residues (L167, V175 in CLK1) of the N-lobe and hydrophobic residues (L295, V324 in CLK1) of the C-lobe resemble the binding of the adenine ring system of ATP co-factor.28 Chemical modifications within the ring of the inhibitors form hydrogen bonds with the main chain atom of the hinge region. The DFG sequence motif in the C-lobe was shown to be essential for inhibitor and substrate binding. It has been reported that the DFG-1 residue (Val in CLK1, 2, 4) is substituted by a shorter side chain Ala in CLK3, which leads to the increased size of the CLK3 binding cavity. This subtle difference has resulted in the development of selective inhibitors on CLK1, −2, and −4 instead of CLK327 (Fig. 1d). Further electrostatic surface calculations showed distinct charge distributions in the binding pocket, indicating that this is likely another important element for selectivity which can be considered during drug design. Taken together, the subtle structural differences in the inhibitor binding site should be considered when designing selective CLK inhibitors in the future.

Biological function of CLKs

CLKs in regulation of the splicing process

Alternative splicing is a biological phenomenon that enables the generation of multiple mRNA and protein products from a single gene.25 Five main types of AS are currently known: ES (exon skipping), IR (intron retention), MXE (mutually exclusive exon), A5SS (alternative 5′ splice site), and A3SS (alternative 3′ splice site).29,30 The spliceosome is an enzymatic machine that is required to splice pre-mRNA.31 Spliceosome formation is the result of complex interactions between small nuclear ribonucleoproteins (snRNPs, including U1, U2, U4/U6, and U5) and more than 150 additional proteins.32 In addition, different RNA-binding proteins (RBPs) take part in alternative splicing, including SR proteins and heterogeneous nuclear ribonucleoprotein (hnRNP) family proteins.31–35 CLKs and SR-specific protein kinases (SRPKs) are largely responsible for phosphorylating the RS dipeptide repeat domains of the SR protein families (SRSF1–12).36 Once phosphorylated, SR proteins regulate RNA splicing and participate in multiple physiological functions.37,38 Besides, other splicing-related factors, such as RBM (RNA binding motif) proteins, are also involved in generating mature mRNA through the process of alternative splicing.35 Additionally, ~95% of human genes transcribe multiple mRNA isoforms by differential inclusion of exons.39 Here, we discuss the involvement of CLKs in regulating the splicing process through phosphorylating splicing-related proteins.

Human CLK1 was shown to regulate the cellular distribution of the SR family proteins via the phosphorylation of their respective C-terminus (Figs. 2 and 3). Among these factors, SRSF1 is a well-characterized downstream substrate of CLKs.25 The N-terminus of CLK1 was shown to interact with SRSF1 through its RS domain which was necessary for the hyperphosphorylation of SRSF1. This process further facilitates the binding of SRSF1 to its RNA target Ron ESE (AGGCGGAGGAAGC), an RNA oligomer designed by the SRSF1 exonic enhancer sequence.25 A phosphoproteomic analysis of gastric tumor and patient-derived xenograft (PDX) samples identified that SRSF2 was hyperphosphorylated in tumor samples. Inhibition of CLK1 by inhibitors or siRNA downregulated CLK1-dependent SRSF2 splicing activity, resulting in a reduced cell proliferation, invasion, and migration of gastric cancer.40 The results indicate the involvement of SRSF2 in CLK1 modulating splicing signals.40 SRSF1 was also shown to be a substrate of CLK2, and its phosphorylation status was observed to be closely related to the expression of CLK2, which is essential for its nuclear localization and splicing functions.41,42 A CLK3-HMGA2 alternative splicing axis was discovered to promote the stemness potential of human hematopoietic stem cells (HSCs) in vitro and in vivo.43 The finding illustrated that CLK3 promoted the skipping of HMGA2-L exon in a SRSF1-dependent manner to reinforce an HSC-specific program. Mutated SRSF1 binding motif within HMGA2-L exon 4 disrupted CLK3 regulated skipping of HMGA2-L through SRSF1, providing a direct molecular link between CLK3 and SRSF1.43 CLK1 phosphorylated SRSF4 and SRSF6 during insulin stimulation resulting in protein kinase C βII (PKCβII) pre-mRNA alternative splicing which subsequently participated in insulin-stimulated actin rearrangements. In addition, CLK1 overexpression promoted exon 17 inclusion splicing and increased the expression of PKCβII through phosphorylation of SR proteins in response to insulin stumilization.5 It was reported that CLK1 phosphorylated SRSF5 on Ser 250, thereby, affecting alternative splicing of METTL14 and Cyclin L2 to promote cell metastasis and viability in pancreatic cancer.44 Inhibition of the CLKs enzymatic activities preferentially inhibited the phosphorylation of SRSF10 at Ser 129, 131, and 133 eliciting p53-dependent apoptosis in human colorectal cancer cells. Moreover, the interaction between CLK1 and SRSF10 was confirmed by a GST-pull-down assay.45Fig. 2 Biology function of CLKs. CLKs participate in biological processes by modulating splicing and non-splicing functions. CLKs are activated, phosphorylated or regulated by c-Myc, AKT or 14–3–3τ, or negatively regulated by miRNAs. CLKs affect their downstream effectors by phosphorylating serine, threonine, or tyrosine residues to activate cellular splicing and non-splicing processes. Alternative splicing of certain genes is increased in response to protein phosphorylation by CLKs. Targets of CLKs include SR proteins, SPF45, and/or U1–70K or modulated RBFOX2. Consequently, different protein isoforms that function in multiple cellular processes are generated. CLKs promote cytokinesis, increase c-myc activity, and suppress fatty acid metabolism by phosphorylating downstream Aurora B, USP13, and PGC-1α. The activation of Wnt/β-catenin and Hippo signaling by increased expression of Wnt 3a or YAP further highlights the importance of CLKs in non-splicing processes. The figure was generated using Figdraw (www.figdraw.com)

Fig. 3 The direct upstream and downstream regulators of CLKs. The expression or activities of CLKs are directly regulated by the upstream proteins such as AKT, c-Myc, or miRNAs. CLKs phosphorylate or modulate their downstream targets, which have been demonstrated in publications, to participate in pivotal processes. The upstream and downstream regulators of CLK1 (a), CLK2 (b), CLK3 (c), and CLK4 (d) have been shown in the figure seperately. The figure was generated by Figdraw (www.figdraw.com)

In addition, CLK kinases were shown to phosphorylate the spliceosome-associated splicing factor 45 (SPF45).46,47 CLK1 phosphorylated SPF45 at eight different Ser residues, facilitating cell migration and invasion in a phosphorylation-dependent manner on SKOV-3 cells. Furthermore, CLK1 enhanced SPF45-induced Fas mRNA exon 6 exclusion to facilitate serum-stimulated cell migration, whereas inhibition of CLK1 promoted SPF45 degradation and inhibited malignant phenotype in a proteasome-dependent manner.46 CLK1 was reported to phosphorylate U1–70K at the C-terminal Ser226 residue, facilitating U1–70K release from subnuclear granules and its subsequent interaction with U1 snRNP and SRSF1 for early spliceosomal protein assembly.48 Furthermore, SR protein kinase 1 (SRPK1) dissociated CLK1 from U1–70K to recycle kinase catalysis.48 Elevated CLK2 mRNA levels were observed in luminal and HER2 + breast cancer cell lines as well as the EGFR-amplified MDA-MB-468 and EGF-dependent MCF10DCIS triple-negative breast cancer (TNBC) cell lines. CLK2 promoted the inclusion skipping at exon 11a of mesenchymal-type ENAH in luminal breast cancer cells through the modulation of RBFOX2 as opposed to SRSF1.42 The usage of ENAH exon 11a affected by CLK2 subsequently implied cell growth, migration, and invasion in breast cancer.42

CLKs in regulation of the nonsplicing process

Besides splicing, the CLKs are involved in other biological functions via phosphorylation of their substrates (Figs. 2 and 3). CLK1, −2, and −4 are required for Aurora B activation via its phosphorylation at the Ser331 residue during late cytokinesis in normally segregating cells.2 Phosphorylation of protein-tyrosine phosphatase (PTP-1B) at Ser50 by CLK1 and CLK2 promoted its enzymatic activity in 32P-labeled in vitro kinase assay, phosphatase assays, and co-transfection experiment in HEK293 cells.49 CLK2 phosphorylated PGC-1α at 11 Ser residues along its SR domain, resulting in the repression of PGC-1α transcriptional activity on gluconeogenic genes and the disruption of the physical interaction of PGC-1α with MED1. This biological process was found to attenuate PPARα transcription, decrease fatty acid oxidation, promote fatty liver disease, and suppress hepatic gluconeogenesis.22,50

AKT kinase exhibits a complex regulatory relationship with CLK1 and CLK2.5,50–53 CLK1 is a preferred substrate of AKT; the AKT phosphorylation site on CLK1 is located in its N-terminal unstructured SR domain but not the kinase domain.5,53 Mutation of the predicted AKT phosphorylation sites of CLK1 to alanine residues (Ser36, Thr122, and Ser139 mutated to Ala) increased PCKβII level throughout the preadipocyte differentiation to mature adipocytes process in 3T3-L1 cells. Furthermore, the S36A mutation of CLK1 resulted in the reduction of SRSF1 and SRSF2 phosphorylation, the T122A mutation led to decrease of SRSF5 phosphorylation, and the S139A mutation contributed to the diminished phosphorylation of SRSF4, SRSF6, SRSF5 as well as SRSF1 and SRSF2 in 3T3-L1 preadipocytes.53 Consequently, the adipogenesis program was blocked prior to differentiation in cells transfected with both CLK1 single mutants and CLK1-AAA mutations.53 AKT was also found to stabilize CLK2 through phosphorylation of CLK2 at Ser34 and Thr127 residues to enhance cell proliferation and block cell apoptosis in response to ionizing radiation.52 In turn, CLK2 was found to phosphorylate the regulatory subunit B56β of phosphatase 2 A (PP2A), which was required to drive AKT-PP2A complex formation that results in AKT dephosphorylation at the Ser473 and Thr308 residues.50,51 Moreover, CLK2 kinase activity was induced by AKT phosphorylation at Thr343 residue of the CLK2 activation loop in response to insulin and feeding in hepatic gluconeogenesis. Once CLK2 was activated, it underwent auto-phosphorylation to stabilize itself.50 Altogether, these results suggested that CLK2 functions as both an up-stream regulator and down-stream substrate of AKT, which operates as a self-regulatory loop. However, this function was probably cell type-specific because no experimental evidence confirming the interaction between CLK2 and AKT was identified in human breast cancer cells.42 In addition, murine CLK2 is auto-phosphorylated at a highly conserved auto-phosphorylation Ser141 site that influences its subnuclear localization; the subcellular localization is suspected to impact substrate interaction properties of CLK2.54 Besides, proteasomal degradation of CLK2 was decreased in glioma stem cells (GSCs) through binding with 14–3–3τ protein.55 Moreover, AKT/ Forkhead box O3a (FOXO3a) /p27 pathway was identified to participate in GSCs growth inhibition which caused by CLK2 knocking down.55 Apart from this, CLK4 bound with nexilin (NEXN) and phosphorylated it at Ser437 to regulate cardiac function, subsequently reversing pathological cardiomyocyte hypertrophy.56

In summary, the role of CLKs in splicing or non-splicing processes is complex and diverse. The general function of CLKs requires the interaction with or phosphorylation of their downstream or upstream proteins. In this review, we summarize the crucial related proteins and potential functions of CLKs in the regulation of cell growth, metastasis, fatty acid oxidation or cardiac function maintain by affecting the activities of downstream proteins (Table 1, Figs. 2, and 3). However, further investigation of CLKs in modulating different proteins or signaling pathways is needed to comprehensively understand the roles that CLKs play in physiological and pathological processes.Table 1 Regulators of CLK proteins

Name	Interaction	Subtypes	Biological function	Ref.	
Downstream regulators	
SRSF1	Downstream of CLK1	Hyperphosphorylation	Hyperphosphorylation of SRSF1 by CLK1 furtherly facilitated the binding of SRSF1 to Ron ESE	25	
Downstream of CLK2	Phosphorylation	Downregulated CLK2 expression decreased the phosphorylation status of SRSF1to inhibit its splicing function	41,42	
Downstream of CLK3	Splicing modulation	CLK3 strongly affected HMGA2 isoforms switching in an SRSF1-dependent manner	43	
SRSF2	Downstream of CLK1	Splicing modulation	CLK1 inhibition decreased SRSF2 expression and downregulated CLK1-dependent SRSF2 splicing activity in gastric cancer cells	40	
SRSF4 and SRSF6	Downstream of CLK1	Phosphorylation	CLK1(Clk/Sty) phosphorylated SRSF4 and SRSF6 during insulin stimulation resulting in exon 17 inclusion and elevated expression of PKCβII	5	
SRSF5	Downstream of CLK1	Phosphorylation at Ser250	CLK1 promoted alternative splicing of METTL14 and Cyclin L2 in pancreatic cancer	44	
SRSF10	Downstream of CLK1	Phosphorylation at Ser129, 131 and 133	CLKs modulated the tumorigenic activity of SRSF10 in human colorectal cancer cells	45	
SPF45	Downstream of CLK1	Phosphorylation at eight serine residues	CLK1 enhanced SPF45-induced Fas mRNA exon 6 exclusion

Inhibition of CLK1 promoted SPF45 degradation via proteasome-dependent proteolysis

	46,47	
U1–70K	Downstream of CLK1	Phosphorylation at Ser226	Facilitated U1–70K released from subnuclear granules and subsequent interaction with U1 snRNP and SRSF1	48	
RBFOX2	Downstream of CLK2	Splicing modulation	Mediated mesenchymal-type ENAH splicing at exon 11a	42	
PTP-1B	Downstream of CLK1/2	Phosphorylation at Ser50	Activated PTP-1B and modulated the enzymatic activity	49	
B56β	Downstream of CLK2	Phosphorylation	Phosphorylation of B56β by CLK2 leads to AKT dephosphorylation at Ser473 and Thr308 sites	50,51	
PGC-1α	Downstream of CLK2	Phosphorylation at 11 serine residues on SR domain	Disrupted the PGC-1α–MED1 interaction and reduced MED1 recruitment to PPARα/PGC-1α promoter resulting in decreased fatty acid oxidation

CLK2 phosphorylated the SR domain of PGC-1α to repress PGC-1α transcriptional activity on gluconeogenic genes in hepatic gluconeogenesis

	49,50

22,50

	
USP13	Downstream of CLK3	Phosphorylation at Y708	Promoted USP13 binding with c-Myc, resulting in the activation of purine metabolic gene transcription in CCA	124	
NEXN	Downstream of CLK4	Phosphorylation at Ser437	CLK4 phosphorylated NEXN at Ser437 to participate in cardiac function regulation	56	
MITF	Downstream of CLK4	Phosphorylation at Tyr360	CLK4 phosphorylated MITF at Tyr360 to promote the degradation of MITF	126	
Aurora B	Downstream of CLKs	Phosphorylation at Ser331	Activated Aurora B during late cytokinesis in normally segregating cells	2	
Upstream regulators	
AKT	Upstream of CLK1	Phosphorylation CLK1 at SR domain (Ser36, Thr122 and Ser139)	AKT phosphorylated the SR domain of CLK1	53	
Upstream of CLK2	Phosphorylation CLK2 at Ser34, Thr127 and Thr343	AKT bond and phosphorylated CLK2 at Ser 34 and Thr 127 in response to ionizing radiation

AKT phosphorylated CLK2 at Thr343 in response to insulin stimulation in hepatic gluconeogenesis

	50–52	
Insulin stimuli	Upstream of CLK2	Phosphorylation CLK2 at Ser342 and Thr343	CLK2 kinase activity was induced by insulin at Ser342/Thr343 in hepatic gluconeogenesis	50	
miR-573	Upstream of CLK2	Regulator	miR-573 bond directly with CLK2 and significantly inhibited the expression of CLK2	121	
14–3–3τ	Upstream of CLK2	Regulator	14–3–3τ bond with CLK2 to prevent the proteasomal degradation of CLK2 and increase protein stabilization in glioma stem cells	55	
c-Myc	Upstream of CLK3	Transcriptional activator	c-Myc overexpression enhanced CLK3 expression	124	
miR-144	Upstream of CLK3	Regulator	miR-144 post-transcriptionally regulated CLK3 to suppress Wnt/β-catenin signaling in hepatocellular carcinoma	125	
MITF	Upstream of CLK4	Regulator (Feedback loop)	MITF bond to the E-boxes in the CLK4 promoter to reduce CLK4 transcript expression in ESCC	126	

CLKs and human diseases

The CLKs exert important functions and participate in various human noncancer diseases and cancer development through splicing or non-splicing processes.57,58 Here, we documented the functions of CLKs and addressed the therapeutic potential of targeting CLKs in various human diseases (Tables 2–4 and Figs. 4–6).Table 2 Summary of CLKs and associated therapeutic strategies in human non-cancer diseases

Human diseases	Compounds	Targets	Phenotype	Mechanism	Cellular model	Animal model	Ref.	
Neurodegenerative diseases	
Alzheimer’s disease (AD)	\	Human and murine CLK2	The expression and activity of CLK2 led to the misregulation of tau exon 10 splicing which contributed to AD	CLK2 related alternative splicing of tau exon 10 was regulated by phosphorylating SR proteins	Transfection of CLK2 plasmids at 2 μg significantly increased the skipping of exon 10 of tau in HEK293 cells	\	59–62	
Phelan-McDermid syndrome (PMDS)	TG003	CLK2	CLK2 targeting improved autism and neuronal functions in PMDS	TG003 recovered spine density in Shank3-deficient neurons by targeting CLK2	10 μM TG003 rescued spine density in Shank3 deficient neurons	\	64	
Indazole 1 and Indazole 2	CLK2		Indazole 1 and -2 elevated spine density in Shank3-deficient neurons by targeting CLK2	Indazole 1 and -2 significantly improved spine density at 300 nM and 1 µM.	\	63	
Duchenne muscular dystrophy	
Duchenne muscular dystrophy (DMD)	TG003	CLKs and SRp30c/SRSF9	TG003 promoted exon skipping only in the c.4303 G > T mutant cells to generate partially functional dystrophin protein	Dephosphorylation of SR protein(s) cooperated with hnRNP A1 to act as a co-inhibitor during the recognition of exon 31, resulting in functional dystrophin protein	Up to 50 μM of TG003 promoted exon 31 skipping in mutated Hela cells and showed no cytotoxicity to cells	Up to 100 mg/kg per day per os showed no toxicity to mice	68	
TG693	CLK1	TG693 promoted the skipping of exon 31 and restored dystrophin expression in patient cells harboring the c.4303 G > T mutation	TG693 targeted CLK1 to reduce downstream SR proteins phosphorylation, resulting in exon-skipping therapy in DMD	TG693 inhibited the phosphorylation of SRSF4 at 5 μM and SRSF6 at 20 μM by targeting CLK1.

Up to 20 μM of TG693 promoted the skipping of exon 31 and upregulated dystrophin expression in patient cells harboring c.4303 G > T mutation

	Oral administration of 30 mg/kg TG693 reduced SRs phosphorylation, particularly SRSF4 in mice

No apparent acute toxicity in rats at up to 100 mg/kg per os

	67	
Inflammatory diseases	
Tendinopathy	SM04755	CLK2 and DYRK1A	SM04755 treatment or knock-down of CLK2 prevented tendon destruction and promoted tendon regeneration in tendinopathy	SM04755 led to intron retention in the mRNA of Wnt pathway genes; decreased tenocyte catabolic enzyme expression; inhibited inflammatory signaling mediators NF-κB and STAT3 by targeting CLK2 and DYRK1A	0.3 μM of SM04755 inhibited inflammatory cytokine production and protected tenocytes from the catabolic breakdown	0.3 mg/cm2 of SM04755 inhibited inflammation and promoted tendon healing in a collagenase-induced acute tendinopathy model in rats	69	
Knee osteoarthritis (OA)	Lorecivivint	CLK2 and DYRK1A	Inhibition or knock-down of CLK2 induced chondrocyte differentiation and suppressed cartilage catabolic enzyme expression	Lorecivivint inhibited CLK2-mediated phosphorylation of SR splicing factors and DYRK1A-mediated phosphorylation of SIRT1 and FOXO1	Lorecivivint inhibited IL-6 and TNF-α production in IL-1β and LPS-stimulated synovial fibroblasts, and LPS-stimulated THP-1 cells in a dose-dependent manner	Intra-articular injection of lorecivivint (0.1 mg, 0.3 mg, 1 mg) decreased phospho-SRSF, phospho-SIRT1, phospho-FOXO1, and phospho-STAT3 in the ACLT + pMMx model and the MIA model of rat knee OA	71,72	
Viral replication	
HIV-1 virus	Chlorhexidine	CLK3 and CLK4, slightly activity against CLK2	CLK3 and CLK4 promoted the expression of HIV-1 Gag and viral RNA abundance	Chlorhexidine significantly inhibited HIV-1 Gag synthesis and suppressed HIV-1 regulatory protein Rev accumulation to prevent virus replication	2.5 μM of chlorhexidine significant repressed HIV-1 replication did not significantly impact cell viability in PBMCs	Chlorhexidine was suggested to applicate on mucosal surfaces to establish well toleration to block HIV-1 in human	81	
Influenza A virus (IAV)	NIH39	CLK1	Inhibition or knock-down of CLK1 reduced the replication of influenza A/WSN/33	NIH39 reduced viral NS mRNA splicing ratio and inhibited viral M1, M2, and NS1 protein levels to suppress viral replication	NIH39 showed antiviral activity with an IC50 of 6.6 μM and reduced viral mRNA splicing and related protein expression at 12.5 μM in A549 cells	CLK1−/− mice showed a reduction of viral replication compared to wild-type C57BL/6 mice	83	
J12098 (Corilagin)	CLK1	J12098 exhibited anti-influenza ability by targeting CLK1	J12098 showed better docking to CLK1 and closely interacted with CLK1	J12098 exerted anti-influenza virus effect with EC50 values of 2.0 ± 2.22 μg/mL a CC50 value of 153.54 μg/mL in vitro	\	86	
J14848 (Pinosylvin)	CLK1	J1484 exhibited anti-influenza ability in vitro by targeting CLK1	J14848 showed better docking to CLK1 and closely interacted with CLK1	J14848 exerted an anti-influenza virus effect with EC50 values of 5.28 ± 2.45 μg/mL and a CC50 value of 18.26 μg/mL in vitro	\	86	
J10688 (Clypearin)	CLK1	J10688 exerted anti-influenza virus activity in vivo and in vitro by potently targeting CLK1	J10688 impaired the synthesis of viral proteins NP and M2 and downregulated the phosphorylation of splicing factors SF2/ASF and SC35	J10688 exerted an anti-influenza virus effect with EC50 values of 1.2 ± 0.28 μg/mL and a CC50 value of >200 μg/mL

3, 10, and 30 μM of J10688 remarkably decreased the NP and M2 expression and reduced the copy number of viral RNA synthesis in a dose-dependent manner

	Mice intravenous treated with 30, 10, and 3 mg/kg/day J10688 showed 91.67% survival rates, whereas all mice died in the normal saline group within 9 days

J10688 administration reduced lung virus titer, enhanced immunological function, and alleviated influenza-induced acute lung injury

	86,87	
Autophagy-associated diseases	
Autophagy-associated diseases	Leucettine L41	CLK1	Leucettine L41 triggered the accumulation of LC3 foci and autophagy by targeting CLK1	Leucettine L41 treatment induced a 150-fold increase of the exon 4-containing CLK1 mRNA to inhibit the activity of CLK1 and induce autophagy	Leucettine L41 induced LC3 foci formation and triggered autophagy in U-2 OS cells without modifying the autophagic flux	\	100	
Compound 9e	CLK1	Compound 9e was an efficient inducer of autophagy	Compound 9e redistributed the location of SR proteins and induced the formation of autophagosome in SKOV-3 cells by targeting CLK1	Compound 9e treatment converted LC3I to LC3II and formed autophagosomes in vitro	\	91	
CLK1-IN-1	CLK1	CLK1-IN-1 treatment increased autophagic flux and induced autophagy	CLK1-IN-1 treatment reduced the phosphorylation and affected the subcellular redistribution of the downstream SR proteins	CLK1-IN-1 elevated the expression level of LC3II protein as well as the ratio of LC3II to LC3I in a dose- and time- dependent manner	CLK1-IN-1 showed hepatoprotective effects on the APAP-induced acute liver injury mouse model.	104	
Other diseases	
Pathological cardiac hypertrophy	\	CLK4	CLK4 deletion led to pathological cardiac hypertrophy	CLK4 regulated cardiac function through phosphorylation of NEXN at Ser437 to restore heart failure	CLK4 formed a complex with downstream NEXN and phosphorylated it at Ser437	Exogenous overexpression of the NEXN (S437E) phosphorylation-mimic mutant in Clk4-cKO mice via AAV9 injection reversed the pathological phenotype induced by CLK4 knockout	56	
Hyperglycemia	\	CLK2	CLK2 was induced by insulin/AKT and acted as a suppressor of hepatic gluconeogenesis	The activated CLK2 phosphorylated PGC-1α at SR domain to repress PGC-1α transcriptional activity on gluconeogenic genes	Insulin/AKT phosphorylated CLK2 at Ser342/Thr343 to stabilize CLK2.	CLK2 was downregulated in the diabetic and obese db/db mice (Leprdb/Leprdb). Re-introduction of CLK2 in the livers of db/db mice dramatically restored the glucose phenotype	50	
Circadian body-temperature oscillations	TG003	CLK1/4	CLK1/4 acted as molecular thermometers in response to circadian body-temperature oscillations	TG003 administration abolished the re-phosphorylation of SRSF5 and SRSF6 as well as exon inclusion and intron retention events during the shift of temperature from 42 °C to 35 °C by targeting CLKs	HEK293 cells with 35 °C TG003 treatment showed a similar temperature dependent AS as 39 °C DMSO samples	Alligator CLK4 activity decreased with the temperature increasing from 27 °C to 35 °C.

Turtle CLK1 showed full activity below 26 °C but lost 90% activity above 31 °C

TG003 prevented the increased intron retention at a colder temperature

	109,110	
os oral solution

Table 3 Summary of expression status, function, and mechanism of CLKs in different cancer types

Kinase	Cancer type	Expression status	Identified gene function	Phenotype	Mechanism	Ref.	
CLK1	Pancreatic ductal adenocarcinoma (PDAC)	Upregulated	Oncogene	Promoted PC cell growth and metastasis in vitro and in vivo

Associated with poor prognosis in PDAC

	CLK1 enhanced phosphorylation on SRSF5Ser250, which inhibited METTL14exon10 skipping while promoting Cyclin L2exon6.3 skipping to promote cancer cell metastasis and proliferation	40,44	
Prostate cancer (PC)	Upregulated	Oncogene	Inhibition of CLK1 decreased cell proliferation and apoptosis in PC3 and DU145 cell lines

CLK1 and CLK3 expression was consistently induced in hypoxic conditions in PC3 cells

	Alternative splicing in cancer related genes: C ENPE, ESCO2, CKAP2, MELK, ASPH and CD164, which contributed to TG003-inhibited cell growth inhibition by targeting CLK1

CLK1 promoted cancer cell adaption to hypoxia by regulating CASP9 alternative splicing

	119,120	
Gastric cancer	Upregulated	Oncogene	CLK1 overexpressed and promoted cell proliferation, migration, and invasion in gastric cancer	CLK1 promoted gastric cancer by modulating its related splicing machinery pathways	40	
Ovarian cancer	/	Oncogene	CLK1 phosphorylated SPF45 to elevate SPF45 expression and promote ovarian cancer migration and invasion	CLK1 phosphorylated SPF45 to increase SPF45 expression and promote SPF45-induced exon 6 exclusion of Fas mRNA in SKOV3 breast cancer cells	46	
CLK2	Non-small cell lung cancer (NSCLC)	Upregulated	Oncogene	Promoted NSCLC occurrence and development	CLK2 overexpression promoted NSCLC growth and acted as a biomarker; miR-573 negatively regulated CLK2 expression in NSCLC	121	
Breast cancer (BC)	Upregulated	Oncogene	Promoted BC growth and EMT phenotype in luminal breast cancer

Pharmacological inhibition of CLK2 decreased cell growth and promoted apoptosis in an allograft model of Myc-driven spontaneous breast cancer

	CLK2 overexpression generated high levels of cyclin B1, CDK1, phospho-Rb, and activated hippo signaling pathway

CLK2 promoted the EMT variant of ENAH to facilitate breast tumor invasion and metastasis

CLK2 inhibition changed the AS of genes involved in cell cycle, DNA repair, RNA splicing, and RNA transport pathways

	42,122	
Glioblastoma and glioma stem-like cell (GSC)	Upregulated	Oncogene	Depletion of CLK2 expression arrested cell cycle at G1 and S phase	Knockdown of CLK2 downregulated AKT/FOXO3a/p27 signaling to interrupt cell cycle and reduce tumor growth

Downregulation of CLK2 decreased the binding affinity of CLK2 with 14–3–3τ, but increased its affinity to phospho-PP2A

	55,123	
CLK3	Cholangiocarcinoma (CCA)	Upregulated	Oncogene	Promoted c-Myc-mediated purine synthesis in CCA	Q607R mutation of CLK3 induced USP13 Y708 phosphorylation, promoted USP13 binding to c-Myc and enhanced c-Myc activity	124	
Hepatocellular carcinoma (HCC)	Upregulated	Oncogene	Increased cell proliferation, migration, and invasion in vitro and tumor development in vivo	CLK3 promoted Wnt 3a expression and activated Wnt/β-catenin cascades in HCC	125	
Hematopoietic stem cells (HSCs)	/	Oncogene	Reinforced an HSC-specific program	CLK3 effected HMGA2 isoform switching; knock-down of CLK3 decreased HMGA2-S but increased HMGA2-L through SRSF1	43	
CLK4	MES-TNBC	Upregulated	Oncogene	Promoted MES-TNBC cell invasion, tumor metastasis, and CSC properties	CLK4 promoted MES-TNBC by overexpression or modulation of TGF-β signaling via SMAD3	114	
ESCC	Downregulated	Suppressor	CLK4 was downregulated in ESCC cells and patient samples. The function of CLK4 in suppressing ESCC development associated with the methylation status of its promoter	CLK4 phosphorylated MITF at Y360 and blocked MITF-enhanced de novo purine synthesis and redox balance	126	

Table 4 Structure and molecular function of CLKs inhibitors

Compound name	Chemical formula	Structure	Targets (IC50 or Kd values)	Administration efficiency	Clinical trial status and efficacy	Ref.	
In vitro	In vivo	
SM08502	C24H25N7O		8 nM on CLK1

2 nM on CLK2

22 nM on CLK3

1 nM on CLK4

2–13 nM on DYRKs

1.1 μM on CDK1

	SM08502 inhibited CLKs activity, decreased SRSF phosphorylation, and reduced the generation of splicing variants of Wnt signal pathway genes in gastrointestinal cancer	Oral administration of 6.25 ~ 25 mg/kg SM08502 by QD or QOD inhibited gastrointestinal tumor growth and decreased SRSF phosphorylation in xenograft mouse models	Phase I (NCT03355066)

Ongoing

Phase I (NCT05084859)

Ongoing

	12,127	
TG003	C13H15NO2S		20 nM on mCLK1

200 nM on mCLK2

15 nM on mCLK4

No activity on mCLK3

No activity on SRPK1, SRPK2 and PKC

	TG003 reduced cell proliferation, invasion, and migration in gastric and prostate cancer cells

TG003 inhibited CLK/STY kinases activities and suppressed phosphorylation of SR proteins in Hela cell line

	Intraperitoneal administration of TG003 twice per week decreased prostate cancer CDX growth	NO	40,47,119,128	
T-025	C21H18N8		0.096 nM on CLK2

4.8 nM on CLK1

6.5 nM on CLK3

0.61 nM on CLK4

0.074 nM on DYRK1 1.5 nM on DYRK1B

	T-025 was more effective on cells with high CLK2 expression and Myc-amplification in a dose-dependent manner; facilitating activation of downstream SE events	50 mg/kg T-025 strongly suppressed the growth of breast tumor allograft model	NO	122	
DB18	C24H18ClN7O3		11 nM on CLK1

27 nM on CLK2

1280 nM on CLK3

20 nM on CLK4

120 nM on DYRK1A

	DB18 showed high inhibitory effects on MCF-7 and PC3 cell lines; weaker inhibitory effects were observed on fibroblast, HuH7, CaCo-2, MDA-MB-231, HCT116 and NCI-H727 cell lines	NO	NO	129,130	
CLK1-IN-1	C24H16FN5O		2 nM on CLK1

31 nM on CLK2

8 nM on CLK4

138 nM on DYRK1A

	CLK1-IN-1 inhibited CLK1 activation, resulting in the distribution of SR proteins and increasing autophagy and autophagic flux	30 mg/kg CLK1-IN-1 had a hepatoprotective effect by decreasing ALT and AST enzyme levels in an APAP-induced hepatotoxicity mouse model	NO	104	
CLK-IN-T3	C28H30N6O2		0.67 nM on CLK1

15 nM on CLK2

110 nM on CLK3

260 nM on DYRK1A

230 nM on DYRK1B

	T3 induced apoptosis and G2/M cell cycle arrest in A2780 and HCT116 cells; synergistically induced apoptosis with Bcl-xL/Bcl-2 inhibitor	NO	NO	131,132	
KH-CB19	C15H13Cl2N3O2		19.7 nM on CLK1

530 nM on CLK3

55.2 nM on DYRK1A

	KH-CB19 suppressed the phosphorylation of SRp75, SRp55 and SRp20; reduced flTF and asHTF expression; attenuated TNF-α-induced TF mRNA splice variants in HMEC-1 cells	NO	NO	117	
Cpd-1	C21H20F3N7O		16 nM on CLK1

45 nM on CLK2

61 nM on SRPK1

75 nM on SRPK2

10000 nM on SRPK3

	Cpd-1, cpd-2, and cpd-3 compounds decreased endogenous phosphorylation of SR proteins and enlarged the nuclear speckles in MDA-MB-468 cells; resulting in splicing alterations of S6K and subsequent S6K protein depletion	NO	NO	133	
Cpd-2	C20H20N6O		1.1 nM on CLK1

2.4 nM on CLK2

>100 nM on SRPK1/2/3

	133	
Cpd-3	C21H21N5O2		1.1 nM on CLK1

2.1 nM on CLK2

>100 nM on SRPK1/2/3

	133	
MU1210	C22H16N4O		8 nM on CLK1

20 nM on CLK2

12 nM on CLK4

>3000 nM on CLK3

29 nM on HIPK2

159 nM on HIPK3

187 nM on HIPK1

213 nM on DYRK1A

956 nM on DYRK1B

1309 nM on DYRK2

	MU1210 attenuated MCF-7 cell proliferation and exhibited an IC50 of 4.6 μM in cell viability	NO	NO	134	
Indazole1	C19H24N4O		12 nM on CLK1

10 nM on CLK2

2250 nM on CLK3

12 nM on CLK4

73 nM on DYRK1A

	Indazole1 increased the frequency of MNBN in a dose-dependent manner through CLKs inhibition in primary human lymphocytes	NO	NO	63	
KuWal151	C16H11ClN2O		88 nM on CLK1,

510 nM on CLK2

28 nM on CLK4

Inactive on CLK3, DYRK1A/B and DYRK2 ( > 10 μM)

	KuWal151 exhibited less than 0.5 μM potency in more than 50 cancer cell lines, specifically in MDA-MB-435 cell line (GI50 = 72.4 nM)	NO	NO	135	
GPS167	C17H13N5OS		NO	GPS167 impaired cell proliferation and organoids growth of human CRC cells by interrupting the phosphorylation of SRSF10	NO	NO	45	
Silmitasertib (CX-4945)	C19H12ClN3O2		3.8 nM on CLK2

1 nM on CK2α and CK2α‘

82.3 nM on CLK1

90 nM on CLK3

1.229 μM on SRPK1 1.111 μM on SRPK2

	CX-4945 inhibited CLK2 kinase activity and modulated SR protein phosphorylation with an IC50 dose between 3 to 90 nM

CX-4945 treatment decreased SRSF1, SRSF4, SRSF5, and SRSF6 phosphorylation in 293 T cells

	CX-4945 inhibited neoplastic animal models singly or synergistically combined with other inhibitors	Phase I/II (NCT03904862) Recruiting

Phase I (NCT03897036) Recruiting

Not application (NCT03571438) Recruiting

Phase I/II (NCT02128282) Complete

	136	
CC-671	C28H28N6O4		6 nM on CLK2

5 nM on TTK

300 nM on CLK1

99 nM on DYRK3

107 nM on DYRK1A

157 nM on DYRK1B

136 nM on PHKG

	Luminal breast cancer cells were more sensitive to CC-671 than TNBC cells	NO	NO	146	
Thiophene 48	C12H8N2S2		110 nM on CLK1

100 nM on DYRK1A

70 nM on DYRK1B

40 nM on DYRK2

	Thiophene 48 induced cell apoptosis in U2OS osteosarcoma cells at 1 μM by increasing the ratio of caspase 3/7

Thiophene 48 exhibited low toxicity on V79 hamster lung fibroblasts at 5 μM

	NO	NO	147	
Leucettine L41	C17H13N3O3		71 nM on CLK1

64 nM on CLK4

60 nM on DYRK1A

44 nM on DYRK1B

73 nM on DYRK2

720 nM on CLK2

>10 μM on CLK3

	L41 displayed a neuroprotective role in glutamate induced HT22 cell death

L41 treatment significantly elevated the percentage of exon inclusion of the CLK1 minigene by modulating pre-mRNA splicing in Hela cells

	NO	NO	148–150	
QD Quaque in Die (every day, once daily), QOD Quaque omni die (every other day)

Fig. 4 Function of CLKs and related inhibitors in human non-cancer diseases. CLKs participate in various human non-cancer diseases including neurodegenerative diseases, inflammatory diseases, Duchenne muscular dystrophy, viral replication, autophagy-associated diseases, and other diseases. CLKs mediate the pathological processes through modulating alternative splicing or changing transcriptional activities. The figure was generated by Figdraw (www.figdraw.com)

Fig. 5 Expression status and clinical outcomes associated with CLKs transcript levels in different tumor types. a RNA-seq data of CLKs expression in tumor and normal tissues were obtained from the TCGA database (https://portal.gdc.cancer.gov/). The Kruskal-Wallis test was used to assess statistical significance. b Raw counts of clinical survival information of CLKs were obtained from The TCGA dataset (https://portal.gdc.cancer.gov/). The KM survival analysis with log-rank test was also used to compare the survival differences between the above two groups. For Kaplan–Meier curves, p values, and hazard ratio (HR) with 95% confidence interval (CI) were generated by log-rank tests and univariate Cox proportional hazards regression. *, ** and *** represented p < 0.05, p < 0.01 and p < 0.001, separately. p < 0.05 was considered statistically significant

Fig. 6 The oncogenic function of CLKs and utilization of CLKs inhibitors in cancer. a–d CLKs participate in cancer development, invasion, and metastasis by altering mRNA splicing, wnt/β-catenin signaling, TGF-β signaling, or mediating cell cycle transition. CLKs regulate cancer growth or metastasis by phosphorylating or modulating their downstream regulators, for instance, SRSF5, SPF45, USP13 SMAD3, PP2A, and other proteins. CLKs inhibitors decreased cancer growth, metastasis, metabolism, and promoted apoptosis by modulating genes participating in cell cycle, EMT, metabolic pathway, and apoptosis, respectively. e Preclinical cancer research conducted to assess the therapeutic potential of CLKs-targeting compounds showed significant tumor growth inhibitory effects. The figure was generated by Figdraw(www.figdraw.com)

CLKs in noncancer diseases and therapeutic tactics

CLKs in neurodegenerative diseases

Hyperphosphorylation and deposition of tau protein is a hallmark of sporadic Alzheimer’s disease (AD), and the dysregulation of tau exon 10 alternative splicing contributes to neurofibrillary degeneration.59 It was also reported that irregular splicing events modulated by CLK1 or CLK2 affected the human adult nervous system contributing to sporadic AD.4,60,61 CLK1-mediated phosphorylation of SR proteins at serine residues is a key mechanism that has been implicated in the development of Alzheimer’s disease.4 In addition, the processes of tau exon 10 alternative splicing induced by phosphorylating SR proteins, and the pre-mRNA splicing changes caused by mCLK2 tended to be therapeutic concepts of tauopathies, including sporadic AD.60,62 Unfortunately, the author of the study did not indicate the exact SRs modulated by mCLK2 in AD. Furthermore, irregular CLK2 expression and activity were observed in AD, which resulting in misregulation alternative splicing of tau exon 1060.

Besides, inhibition of CLK2 was proposed to be a potential therapeutic strategy in Phelan-McDermid syndrome (PMDS) by improving autism and neuronal functions.63 The loss of ubiquitination modulation of CLK2 expression in Shank3-deficient neurons is a genetic hallmark of PMDS. Moreover, TG003 treatment exhibited a similar restorative effect on spine density with CLK2 reduction in Shank3- deficient neurons.64 On the basis that CLK2 is a therapeutic target of PMDS, Indazole 1 and Indazole 2 were shown to increase spine density in mouse brain slices at a relatively low dose (300 nM and 1 µM) compared to TG003 (10 µM).63

CLKs in Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a fatal progressive muscle-wasting disease. Based on current research, DMD develops due to open-reading frame disruption or dystrophin mRNA alteration caused by exon deletion or mutations.65,66 CLK1-regulated splicing manipulation, especially the exon-skipping function, was reported to contribute to DMD.67 A patient harbored c.4303 G > T point mutation in dystrophin gene exon 31 changed SRp30c/SRSF9-dependent exon skipping enhancer (ESE) to hnRNP A1-dependent exon skipping silencer (ESS), thus, leading to exon 31 skipping to generate truncated, but functional dystrophin protein. Moreover, TG003, an inhibitor of CLK-1, −2, and −4, promoted dystrophin gene exon 31 skipping in patient muscle cells that harbored the c.4303 G > T point mutation (ineffective in exon 31-WT cells) and enabled the generation of partially functional dystrophin protein.68 On the other hand, additional SR(s) which could be phosphorylated by CLKs cooperated with hnRNP A1 to recognize exon 31 during splicing after de-phosphorylation by TG003.68 TG693, a selective CLK1 inhibitor capable of treating DMD, was discovered to be a more metabolically stable compound relative to TG0003.67 Functionally, TG693 mediated SR protein phosphorylation and promoted mutant exon 31 skipping reading on the cells harboring the c.4303 G > T point mutation by targeting CLK1, particularly SRSF4 and SRSF6.67 These efforts highlight the potential benefits of using CLKs-targeting compounds for the therapeutic management of genetic diseases characterized by irregular splicing, including DMD.

CLKs in inflammatory diseases

Knockdown of CLK2 promoted tenocyte differentiation by inhibiting the expression of tenocyte catabolic enzymes, indicating that targeting CLK2 may play a protective role against tendinopathy.69 SM04755 was identified as a potent inhibitor of CLK2 and DYRK1A with an IC50 of 5.0 nM and 3.5 nM, respectively. SM04755 potently inhibited CLK2 and DYRK1A to modulate intron retention of Wnt pathway genes, subsequently suppressing Wnt signaling pathway and inhibiting the inflammatory signaling mediators NF-κB and STAT3. This process prevented tendon destruction and promoted tendon regeneration.69

Osteoarthritis (OA) is a disease characterized by the formation of osteophytes, cartilage degradation, and synovial inflammation.70 CLK2 and DYRK1A participate in OA through the Wnt pathway without modulating β-catenin activity, resulting in inflammatory cytokine production and cartilage catabolic enzyme expression.71,72 In addition, CLK2 inhibition suppressed cartilage catabolic enzyme expression and induced early chondrocyte differentiation in human mesenchymal stem cells (hMSCs).71 This finding reveals a novel role of CLK2 in promoting OA. Lorecivivint (SM04690) potently inhibited CLK2 (IC50 = 7.8 nM) and DYRK1A (IC50 = 26.9 nM) to suppress CLK2-mediated phosphorylation of SR proteins and DYRK1A-mediated phosphorylation of SIRT1 and FOXO1. Moreover, Lorecivivint exerted anti-inflammatory effect by significantly decreasing NF-κB and STAT3 activity. Lorecivivint provided both symptom relief and inflammatory modification through dual targeting of CLK2 and DYRK1A.62

A Phase I clinical trial (NCT02095548) and phase IIa proof‐of‐concept clinical trial (NCT02536833) among knee OA patients indicated that Lorecivivint appeared to be safe and well-tolerated, emphasizing the therapeutic potential of Lorecivivint in OA.73,74 A post hoc analysis from a phase IIb clinical trial (NCT03122860) showed that intra-articular (IA) therapy of 0.07 mg Lorecivivint in participants with knee OA showed long-lasting improvements in function and pain compared to those given placebo.75,76 Furthermore, other clinical trials (NCT04385303 (Phase III), NCT03928184 (Phase III), NCT03727022 (Phase II) and) have been carried out and accomplished to reveal the therapeutic potential of Lorecivivint in keen OA.

CLKs in viral replication

The HIV-1 virus significantly contributes to the global health burden and the replication of HIV-1 is the key process in the virus life cycle.77,78 Substantial efforts have been made to alter RNA splicing of HIV-1, and SR proteins were found to participate in viral replication.79,80 Therefore, studies were carried out to investigate the role that CLKs, which are located upstream of SRs, play in HIV-1 replication. CLK1 promoted the expression of HIV-1 Gag, a viral structural protein, while CLK2 significantly decreased Gag expression. However, CLK3 and CLK4 were found to only have modest effects in promoting Gag expression.81 Application of chlorhexidine, an inhibitor of CLK2, −3, and −4 (chlorhexidine exhibits minimal activity against CLK2), significantly inhibited HIV-1 Gag synthesis and viral replication. Moreover, chlorhexidine treatment suppressed HIV-1 regulatory protein Rev accumulation to prevent the export of viral RNAs. Moreover, a phase II clinical trial (NCT00006075) was carried out at the year of 2001 to evaluate the best strength of chlorhexidine gluconate in the prevention of mother-to-child transmission (MTCT) of HIV-1 by washing the mother’s vagina and the newborn baby during birth. The trial pointed out that a 1% solution of chlorhexidine exhibited well safety, tolerance, and effectiveness in decreasing the rate of MTCT of HIV-1.82 These findings highlight the possibility of targeting host CLKs to block HIV-1 replication.81

The life cycle of influenza A also relies on mRNA splicing and splicing-related factors, including CLK1.83–85 Knock-down of CLK1 reduced the replication of influenza A/WSN/33 by increasing segment 7 RNA splicing and decreasing viral M1 and M2 proteins, which are essential for influenza virus replication. Furthermore, SRSF3 was identified as a key factor responsible for regulating viral RNA splicing upon CLK1 inhibition. NIH39 and KH-CB19, inhibitors of CLK1, showed antiviral activity with an IC50 of 6.6 μM and 13.6 μM, respectively. NIH39 reduced viral mRNA splicing and related protein expression at 12.5 μM. However, KH-CB19 did not show any effect even at relatively high doses of 50 and 100 μM, indicating that NIH39 may be a promising anti-viral therapeutic to combat influenza A.83 As CLK1 was found to play a crucial role in influenza replication, screening of CLK1 inhibitors was carried out by a virtual docking program. The virtual docking program indicated that J10688 (clypearin), J12098 (corilagin), and J14848 (pinosylvin) were identified to be the most potential anti-influenza virus candidates as CLK1 inhibitors with EC50 values of 1.2 ± 0.28, 2.0 ± 2.22 and 5.28 ± 2.45 μg/mL, respectively; cytotoxic concentrations (CC50) were >200, 153.54 and 18.26 μg/mL, respectively.86 J10688, isolated from Pithecellobium clypearia Benth, showed potent anti-influenza ability through impairing viral proteins NP and M2 synthesis and downregulating the phosphorylation of the splicing factors SF2/ASF and SC35.87 These conclusions indicated a novel therapeutic approach that targets host CLKs to suppress viral replication.

Besides HIV-1 and influenza A, CLK1 also plays important roles in the replication of West Nile virus and chikungunya virus, making it an attractive cellular candidate for host-directed antiviral therapy.88–90

CLKs in autophagy-associated diseases

Autophagy is an important cellular process that protect cells from death and maintain homeostasis through the selective degradation of intracellular hazard.91 Alterations in autophagic activity are associated with a wide range of human diseases, including diabetes,92,93 cardiovascular diseases,94,95 infectious96,97 and drug-induced organ injury.98,99 CLK1 has been reported to participate in the regulation of the autophagy process. CLK1 inhibition by 10 μM concentration of Leucettine L41 (inhibit both DYRKs and CLKs) treatment was shown to increase LC3 foci formation and induce autophagy in a dose-dependent manner in human osteosarcoma cells U-2 OS.100 Meanwhile, CLK1 RNA interference in U-2 OS cells resulted in elevated cell autophagy. However, Leucettine L33 (inactive on both CLK1 and DYRKs) and L38 (more potent to DYRKs) were unable to trigger autophagy in U-2 OS cells.100 The findings highlight that CLKs inhibition contribute more to autophagy than DYRKs. Mechanistically, L41 treatment significantly elevated exon 4-containing CLK1 mRNA transcripts resulting in an increase of the full-length kinase isoform by modulating its own splicing.100,101 Additionally, the targeting of CLK1 by inhibitors or siRNA reagents was speculated to trigger autophagy through modulating the alternative splicing of autophagy regulator pre-mRNAs, including mTOR and X-box–binding protein 1 (XBP1).100,102,103 These findings further confirm that CLK1 inhibitors are potent inducers of autophagy. Moreover, compound 9e, a drug derived from 3,6-disubstutited-imidazo [1,2-α] pyridine, potently inhibited CLK1 with an IC50 value of 4 nM compared with CLK2 (IC50 of 50 nM) and CLK4 (IC50 of 17 nM). Treatment with compound 9e induced autophagy, significantly increased autophagic flux, and affected the subcellular redistribution and phosphorylation levels of the downstream SR proteins of CLK1 in SKOV-3 cells.91 In addition, CLK1-IN-1 was shown to induce autophagy by targeting CLK1 in the treatment of autophagy-associated diseases. The downstream SR proteins of CLK1 were redistributed from the nucleoplasm to nuclear speckles after CLK1-IN-1 treatment. Furthermore, CLK1-IN-1 induced autophagy in BNLCL.2 and SKOV-3 cells by elevating LC3II protein expression and increasing the ratio of LC3II to LC3I in a dose- and time-dependent manner by targeting CLK1.104 Collectively, inhibition of CLK1 increased cellular autophagy, indicating its potential as a treatment strategy for autophagy-associated diseases.

CLKs in other diseases

Pathological cardiac hypertrophy is characterized by hypertrophic growth and cardiomyocyte size increase in response to pathological stimuli.105,106 CLK4 was found to play a pivotal role in maintaining cardiac function; the deletion of CLK4 contributed to pathological myocardial hypertrophy and heart failure.56 Phosphorylation of NEXN at Ser437 by CLK4 was found to rescue pathological myocardial hypertrophy, which highlights the splicing-independent involvement of CLK4 in heart disease. Moreover, the finding indicated that restoration of CLK4 may act as a novel therapeutic target for treating pathological cardiac hypertrophy.56

Hepatic gluconeogenesis is critical for hyperglycemia in diabetes.107,108 CLK2 was identified as a suppressor of hepatic gluconeogenesis, and its activity was regulated by insulin/AKT.50 Insulin/AKT stabilized CLK2 and increased its expression and activity during the feeding/fasting nutrient cycle. Mechanistically, Insulin treatment led to CLK2 phosphorylation at Ser342/Thr343 in H2.35 hepatocytes. Moreover, AKT specifically interacted with CLK2 at its kinase domain and phosphorylated CLK2 at Thr343 in response to insulin. Activated CLK2 phosphorylated PGC-1α at its SR domain to repress PGC-1α transcriptional activity on gluconeogenic genes, resulting in hepatic gluconeogenesis suppression.50

Furthermore, CLKs contributed to the sensing of temperature differentials through the phosphorylation of SR proteins.109 CLK1/4 became completely inactivated at 38 °C and was re-activated at 35 °C, indicating the potential role of CLK1/4 as molecular thermometers in response to circadian body-temperature oscillations.109,110 TG003 application dramatically abolished the re-phosphorylation of SR proteins, such as SRSF5 and SRSF6, during the temperature shift from 42 °C to 35 °C.109 Meanwhile, temperature-dependent AS events, including exon inclusion and intron retention, were modulated after TG003 treatment, illustrating the pivotal role of CLK1/4 in connecting body temperature with AS.109

To summarize, irregular splicing or expression of CLKs involved in various human diseases, for instance, Alzheimer’s disease, osteoarthritis, Duchenne muscular dystrophy, pathological cardiac hypertrophy, and gluconeogenesis. Moreover, inhibitors have been reported to have anti-inflammatory, anti-viral, and anti-neurodegenerative functions as well as other functions. Nevertheless, the clinical application of these inhibitors is in great demand which may provide direct evidence for the therapy of different human diseases.

CLKs in cancer and treatment strategies

Expression or activities change of CLKs are associated with cancer development and progression.111–115 Depletion or chemical inhibition of CLKs changed alternative splicing events leading to decreased cell proliferation.67,116–118 Given the expression status and clinical significance of CLKs in The Cancer Genome Atlas Program (TCGA) database (https://portal.gdc.cancer.gov/), we systematically discuss the roles of CLKs in cancer and therapeutic effects of their related inhibitors (Table 3 and Figs. 5, 6).

CLK1 in cancer

The expression of CLK1 was dramatically increased in pancreatic ductal adenocarcinoma (PDAC) tissues at both the mRNA and protein levels, promoting cell growth and metastasis in vitro and in vivo.44 High expression of CLK1 was associated with poor prognosis in PDAC. Mechanistically, CLK1 was found to directly phosphorylate SRSF5 at Ser250. Consequently, this inhibited METTL14exon10 skipping (generated METTL14-L isoform) to enhance N6-methyladenosine (m6A) methylation and cancer metastasis. Additionally, Cyclin L2exon6.3 skipping (generated CCNL2-S isoform) was found to promote PDAC cells proliferation in response to SRSF5 phosphorylation at Ser250.44 These results revealed a therapeutic option and potential prognostic value of CLK1/SRSF5 pathway in PDAC patients.

Inhibition of CLK1 decreased cell proliferation and induced apoptosis in PC3 and DU145 prostate cancer cells; the responsive AS events were validated by transcriptomic analysis.119 The sequencing revealed the dramatic change of alternative splicing events in the following cancer related genes: centromere protein E (CENPE, inclusion at exon 38), establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2, skipping at exon 9), cytoskeleton associated protein 2 (CKAP2, skipping at exon 3), maternal embryonic leucine zipper kinase (MELK, skipping at exon 13), aspartate β-hydroxylase (ASPH, skipping at exon 6 and 8) and CD164 (skipping at exon 5).119 In hypoxic conditions, CLK1 and CLK3 expression were consistently induced in PC3 cells exposed to 1%, 0.2%, and 0% hypoxic environments; changes in CASP9 splicing were also observed.120

CLK1 was expressed at levels 10 to 30% higher in gastric tumor samples compared to normal gastric tissues.40 In a phosphor-proteomic analysis study, CLK1 and its related splicing machinery pathway were shown to be the most important regulators in gastric cancer.40 CLK1 was overexpressed in gastric cancer tissues and the inhibition of CLK1 resulted in the suppression of cell proliferation, migration, and invasion.40 These findings indicate that CLK1 plays an important role in gastric cancer progression.

SPF45 was identified to be a cellular target of CLK1 in ovarian cancer.46,115 (LC)-electrospray ionization-tandem mass spectrometry (MS/MS) experiments showed that CLK1 is able to phosphorylate SPF45 at eight serine residues (Ser 48, 62, 202, 204, 222, 266, 288, and 291).46 Furthermore, CLK1 overexpression increased SPF45 protein levels and promoted SPF45-induced exon 6 exclusion of Fas mRNA in SKOV3 breast cancer cells. Additionally, inhibition of CLK1 decreased the half-life of SPF45 via a proteasome-dependent manner in both SKOV-3 and HeLa cells. Interestingly, kinase dead Ser 48/222/266 mutants significantly increased exon 6 exclusion while Ser 202/204 A significantly decreased exon 6 exclusion compared with wild-type Myc-SPF45 in COS-1 cells. The finding further illustrates that CLK1 differentially regulates SPF45 splicing activity depending upon phosphorylation at different serine sites. Moreover, SPF45 enhanced fibronectin expression to promote ovarian cancer migration and invasion in a CLK1 phosphorylation-dependent way.46 This finding highlights the potential use of CLK1 inhibitors to dephosphorylate SPF45 in ovarian cancer treatment.

Based upon data provided by TCGA, CLK1 is significantly overexpressed in many cancer types, including cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ) and stomach adenocarcinoma (STAD) (Fig. 5a). In addition, CLK1 was considered to participate in the onset, progression, and evolution of cancers through different mechanisms, however, the function probably was cancer specific.

CLK2 in cancer

Increased expression of CLK2 was demonstrated to be correlated with poor prognosis in non-small cell lung cancer (NSCLC).121 In addition, CLK2 expression was elevated in patients with late-stage (III–IV) cancer and metastasis, indicating that CLK2 could be a potential biomarker in NSCLC. Moreover, miR-573 suppressed CLK2 expression and interrupted the occurrence and development of lung cancer caused by CLK2 overexpression.121

In luminal breast cancer, overexpression and amplification of CLK2 were demonstrated to promote cell proliferation, migration, invasion, and xenograft growth.42 Breast cancers which harbored high CLK2 expression levels showed a more proliferative phenotype based on increased levels of cyclin B1, CDK1, phospho-Rb, and the activation status of hippo signaling pathway.42 Moreover, CLK2 was found to promote the EMT variant of ENAH to facilitate breast tumor invasion and metastasis.42 Pharmacological inhibition of CLK2 resulted in significant growth inhibition, apoptosis, and exon skip in the allograft model of Myc-driven spontaneous breast cancer.122 RNA-seq analysis also revealed that genes involved in cell cycle, DNA repair, RNA splicing, and RNA transport pathways were modulated in alternative splicing, further indicating the potential role of AS by CLK2 in breast cancer.122

The cell cycle of glioblastoma cell lines with elevated CLK2 levels was arrested at G1 and S phases as a consequence of CLK2 depletion.123 Mechanistically, knockdown of CLK2 was shown to interrupt the cell cycle in vitro through the downregulation of AKT/FOXO3a/p27 signaling, resulting in reduced glioblastoma tumor growth and prolonged survival in vivo.123 Moreover, CLK2 expression in glioblastoma patient specimens was inversely correlated with patient survival time.123 In addition, 14–3–3τ directly bond with CLK2 to increase CLK2 stability through modulating proteasomal degradation in glioma stem-like cells (GSCs).55 Meanwhile, CLK2 negatively regulated PP2A activity in the GSC272 brain tumor cancer cell line. Downregulation of CLK2 led to decreased binding affinity with 14–3–3τ and increased binding affinity with phosphor-PP2A, resulting in the activation of PI3K signaling pathway. Thus, the combination of CLK2 depletion with the PI3K/mTOR inhibitor GSK2126458 significantly reduced tumor growth in GSC272-implanted mice. Furthermore, the induction of apoptosis was also observed when FGFR inhibitor (LY2874455) was administered to a CLK2 knockdown GSC mouse model.55

RNA-Seq data provided by the TCGA has shown that CLK2 is overexpressed in many cancer types (Fig. 5a). Increased expression of CLK2 was correlated with poor clinical outcomes in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), COAD and KIRC (Fig. 5b). In conclusion, CLK2 might be an ideal therapeutic target and prognostic marker for cancer treatment.

CLK3 in cancer

CLK3 was found to be upregulated in cholangiocarcinoma (CCA) patients and plays a role in nucleotide metabolism.124 Meanwhile, a gain of function somatic mutation Q607R was identified in CLK3 kinase domain, which induced USP13 Y708 phosphorylation and promoted USP13 binding to c-Myc. The binding was found to prevent c-Myc ubiquitination and enhance c-Myc activity, thereby, increasing c-Myc-mediated purine synthesis in CCA.124 In turn, a CLK3-USP13-c-Myc feedback loop was identified whereby activated c-Myc increased CLK3 transcription by enhancing CLK3 promoter activity. However, the other CLKs family members were not affected by c-Myc.124

CLK3 was also markedly upregulated and closely associated with hepatocellular carcinoma (HCC) TNM stages and patient prognosis.125 Functional analysis revealed that CLK3 promoted Wnt 3a transcription and activated Wnt/β-catenin cascades, resulting in increased HCC cell proliferation, migration, and invasion in vitro; additionally, animal experiments showed that CLK3 also increased tumor development in vivo. Moreover, the miR-144/CLK3 axis was found to further attenuate Wnt/β-catenin signaling, resulting in suppression of HCC development and metastasis.125

CLK3 also affected HSCs by modulating HMGA2 alternative splicing.43 Mechanistically, CLK3 strongly affected HMGA2 isoform switching; knock-down of CLK3 decreased HMGA2-S transcription but increased HMGA2-L transcription through SRSF1. The results indicated that CLK3 was involved in regulating an SRSF1-dependent splicing pattern that enhanced the development of human HSC.43

Summarization from the TCGA database demonstrated that elevated expression of CLK3 was observed in CHOL, HNSC, Kidney chromophobe (KICH), KIRC, KIRP, LIHC, PRAD, and STAD. Furthermore, increased expression of CLK3 was correlated with poor overall survival (OS) outcome in COAD, indicating the clinical significance of CLK3 (Fig. 5). Thus, targeting CLK3 by siRNA or antagonists could be taken into consideration for further investigation.

CLK4 in cancer

CLK4 was overexpressed in mesenchymal-like TNBC (MES-TNBC) cells and correlated with poor patient survival.114 Silencing of CLK4 in a xenograft mouse model was shown to decrease the expression of multiple epithelial-mesenchymal transition (EMT) genes which participate in metastasis and repress tumor cell migration in TNBC cells.114 Notably, depletion of CLK4 impaired the expression of SMAD3, a mediator of TGF-β signal transduction, suggesting that overexpression of CLK4 can promote metastatic and aggressive phenotypes in MES-TNBC cells. Furthermore, the pharmacological inhibition of CLK4 suppressed the growth and invasiveness of MES-TNBC cells, highlighting the potential utilities of CLK4 in the clinic.114

CLK4 was also found to be extensively downregulated in esophageal squamous cell carcinoma (ESCC) cells and patient samples due to the methylation of its promoter.126 Mechanistically, CLK4 phosphorylated microphthalmia-associated transcription factor (MITF) at Tyr360 to promote the autophagy degradation of MITF. As a feedback axis, MITF bond to the E-boxes in CLK4 promoter transcriptionally downregulating the expression of CLK4 in ESCC. Moreover, CLK4 was proved to be a redox-sensitive kinase. Interestingly, impairment of CLK4 kinase activity upon oxidation of Met307 was found to enhance ESCC carcinogenesis.126 This finding revealed a novel function of CLK4 in modulating purine synthesis and redox status in conjunction with its role in alternative splicing.

CLK4 expression varied in different cancer datasets, among which the expression was significantly elevated in CHOL, glioblastoma multiforme (GBM), HNSC, KIRC, KIRP, LIHC, PRAD, and STAD; Conversely, CLK4 transcription was reduced in BLCA, breast invasive carcinoma (BRCA), lung squamous cell carcinoma (LUSC), pheochromocytoma and paraganglioma (PCGC), thyroid carcinoma (THCA) and uterine corpus endometrial carcinoma (UCEC) (Fig. 5).

The frequency of elevated CLKs expression in gastric, prostate, lung, and cholangiocarcinoma patient tumor tissues40,42,119–121,124 suggests that CLKs may directly or indirectly contribute to tumor development, progression, or metastasis. Besides, mutation (CLK3)124 or post-translational modification (CLK4) of CLK,126 alteration of CLKs expression or function influenced tumor phenotypes. Therefore, high throughput sequencing and chemical development based on mutation sites might be an effective method to highlight clinically relevant molecular features of CLKs.

Targeting CLKs for cancer therapeutic strategies

The large body of evidence provided in this review has illustrated the major oncogenic function of CLKs in cancer. Thus, targeting CLKs has garnered increased attention from clinical researchers as a potential method of treating several cancer types. A number of inhibitors that generally bind in the CLKs ATP pocket have been extensively studied and reported (Table 4, Figs. 1b and 6).

SM08502 (Cirtuvivint) is the first small molecular inhibitor of CLKs which underwent clinical trials. SM08502 is a potent pan-CLKs inhibitor and showed strong affinity for CLKs with IC50 values of 8 nM to CLK1, 2 nM to CLK2, 22 nM to CLK3, and 1 nM to CLK4.127 Although SM08502 showed high affinity to CLKs, it inhibited the activity of other structurally similar kinases as well, indicating off-target effects and the potential for cytotoxicity.12,127 SM08502 was shown to significantly inhibit the kinase activity of CLKs and decrease SRSF phosphorylation in gastrointestinal cancers. Furthermore, SM08502 disrupted spliceosome activity, thus, reducing the generation of splicing variants of Wnt signal pathway genes.127 Oral administration of SM08502 significantly inhibited the growth of gastrointestinal tumors. SM08502 also decreased SRSF phosphorylation and Wnt pathway gene expression in xenograft mouse models, suggesting that SM08502 is a potent therapeutic drug in cancer treatment.127 A Phase I clinical trial of SM08502 (NCT03355066) assessing its efficacy in treating advanced solid tumors for whom no standard therapy is currently underway. This trial aimed to evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 by oral administration. Additional clinical trials (NCT05084859) for castration-resistant prostate cancer, non-small cell lung cancer, and colorectal cancer were posted in 2021 to evaluate the safety, tolerability, PK, and preliminary anti-tumor efficacy of SM08502.

TG003, a benzothiazole compound, was found to have a potent inhibitory effect on CLK1 and CLK4 via in vitro phosphorylation assay.128 The activities of TG003 on different CLKs and other kinases, including SRPKs and PKC, were evaluated. Results showed strong inhibitory activity of TG003 on murine CLKs (mCLKs) with IC50 values of 20 nM on mCLK1, 200 nM on mCLK2, and 15 nM on mCLK4; however, TG003 showed less inhibitory activity against mCLK3, SRPK1, SRPK2, and PKC kinases.128 Moreover, TG003 acted on CLK1/Sty kinase competitively with ATP (Km 3.35 μM) with a Ki value of 10 nM.128 In addition, 10 μM TG003 inhibited Clk/Sty kinase activity and SR protein phosphorylation in Hela cell.128 TG003 was also found to inhibit CLK-dependent alternative splicing and serine/arginine-rich protein phosphorylation.128 The application of TG003 significantly decreased gastric cancer cell viability, invasion, and migration. Similar inhibition effects were found in gastric cancer after depletion of CLK1 by small interfering RNA (siRNA).40 Mechanistically, TG003 treatment led to the decrease of splicing protein pSRPK2, SRSF2, CLK1, and p-AKT.40 In prostate cancer (PC), TG003 reduced cell proliferation, induced apoptosis, and reversed EMT markers in vitro; in vivo CDX tumor growth was also decreased upon treatment with TG003.119 In addition, TG003 was found to regulate the alternative splicing of CLK1 mRNA by reducing intron 4 retention and exon 4 skipping, resulting in altered production of full-length catalytically active (CLK1T1) and truncated catalytically inactive (CLK1T2) isoforms.47

T‐025, a chemical modified from the 7H‐pyrrolo [2,3‐d] pyrimidine structure, was developed as a potent inhibitor of CLK2 able to bind within the ATP-binding pocket and interact with the Glu244 and Leu246 amino acid residuess.122 The Kd values of T-025 to CLK1, -2, -3, -4 were 4.8, 0.096, 6.5, and 0.61 nM, respectively; low Kd values to DYRKS family proteins were also observed.122 As a highly potent inhibitor to CLK/DYRK1, T-025 exhibited more than 300-fold enhanced selectivity compared with other kinases during a KINOMEScan-based kinase profiler assay.122 T-025 was more sensitive to the cells with elevated CLK2 expression and Myc-amplification in a dose-dependent manner.122 Additionally, 50 mg/kg T-025 strongly suppressed the growth of a breast tumor allograft model suggesting that T-025 exerts anticancer effects against Myc-driven breast cancers.122

DB18 is a potent inhibitor of CLK1, -2, and -4 kinases belonging to the nilino-2-quinazoline derivatives.129 DB18 attenuated CLKs kinase activities with IC50 values of 11 nM on CLK1, 27 nM on CLK2, 1280 nM on CLK3, and 20 nM on CLK4 based on radiometric γ33P-ATP assay.129 When screening at 10 μM concentration with 10 μM ATP, the compound also showed slight affinity to DYRK1A at 120 nM.129,130 Surprisingly, high DB18 concentrations (100 μM) showed no toxicity on the activity of both human and rat DYRK1A, human DYRK1B, and DYRK2. Therefore, DB18 may be considered a novel and promising CLKs selective inhibitor.129 A cytotoxicity screening assay of DB18 was carried out in different cancer cell lines and normal human fibroblast.129 The data demonstrated that DB18 exhibited potent cytotoxicity on MCF-7 and PC3 cell lines with IC50 values of 4 and 7 μM. Moreover, DB18 showed moderate cytotoxicity on fibroblast and HuH7 at 21 and 25 μM, and weak activity on CaCo-2, MDA-MB-231, HCT116, and NCI-H727 with IC50 higher than 25 μM.129 The variability of DB18 efficacy across cell lines is likely dependent on the CLKs expression levels and kinase activities.

CLK1-IN-1 was designed as a potent and selective inhibitor of CLK1 with an IC50 of 2 nM. The activity of CLK1-IN-1 against its targets is highly dependent on the residues comprising the kinase domains.104 CLK1-IN-1 strongly suppressed CLK1 kinase activity with 69-fold higher in activity compared to the inhibitory effect of CLK1-IN-1 against DYRK1A (IC50 = 138 nM).104 CLK1-IN-1 was also shown to inhibit other CLKs activities with IC50 values of 31 nM to CLK2 and 8 nM to CLK4.104 Treatment of BNL CL.2 (mouse embryonic liver cell) with 10 μM CLK1-IN-1 significantly inhibited CLK1 activation, resulting in the redistribution of SR proteins from the nucleoplasm to nuclear speckles, and an increase of autophagy and autophagic flux in vitro in a dose-dependent manner.104 Meanwhile, CLK1-IN-1 elevated LC3II expression and induced autophagy and autophagic flux in a dose- and time-dependent manner in the SKOV-3 human ovarian cancer cell line, indicating its therapeutic potential for treating certain cancers.104 Furthermore, CLK1-IN-1 (30 mg/kg) was reported to have a hepatoprotective effect by decreasing alanine aminotransferase (ALT) and aspartate aminotransferase (AST) expression levels in an Acetaminophen (APAP)-induced hepatotoxicity mouse model.104

CLK-IN-T3 exhibited dramatic inhibitory activity against CLKs with IC50 values of 0.67 nM for CLK1, 15 nM for CLK2, and 110 nM for CLK3, respectively. However, the change in CLK4 activity post-T3 treatment was not directly measured in that work.131 DYRK1A and DYRK1B, dual specificity kinases of the CMGC sub-family, were inhibited 200–300 times less efficiently than CLKs based on kinase enzymatic assays.131 The results of RNA-Seq analysis indicated that distinct RNA-binding motifs in skipped exons were associated with T3 treatment.131 Meanwhile, T3 application decreased the phosphorylation of the SR proteins, which are located downstream of CLKs. T3 induced apoptosis and G2/M cell cycle arrest in human A2780 and HCT116 cells by targeting CLK.131 Mechanically, T3 application modified AS events in cancer by decreasing the expression of the anti-apoptotic forms of cIAP1, cIAP2, XIAP, cFLIP, and Mcl-1.132 Meanwhile, T3 synergistically induced apoptosis together with Bcl-xL/Bcl-2 inhibitor in human HCT116 and A2780 cancer cells.132

KH-CB19 is a potent and highly selective CLKs inhibitor that was demonstrated to strongly bind with CLK1 and CLK4 in temperature shift assays.117 Further enzymatic assay revealed a relatively lower IC50 on CLK1 compared with IC50 values of 530 nM on CLK3 and 55.2 nM on DYRK1A.117 KH-CB19 was revealed to bind with the ATP-binding sites of CLK1 and CLK3 based on co-crystal structures. Further experiments demonstrated that 10 μM KH-CB19 suppressed the phosphorylation of SRp75, SRp55, and SRp20 compared to TG003, which only inhibited SRp20 phosphorylation. Additionally, 10 μM KH-CB19 was able to inhibit full-length tissue factor (flTF) and alternatively spliced human tissue factor (asHTF) expression in HMEC-1 cells.117 KH-CB20, an E/Z-mixture compound, shared the same structure and similar kinase binding affinity with E-isomer KH-CB19 with IC50 values of 16.5 nM on CLK1, 488 nM on CLK3 and 57.8 nM on DYRK1A.117 These results illustrated the potential of KH-CB19 and KH-CB20 as lead compounds for further drug development.

Cpd-2 and cpd-3 possessed high affinity to CLK1/2 compared to SRPK1/2/3 with IC50 values of 1.1 nM (both cpd-2 and cpd-3), 2.4 nM (cpd-2) or 2.1 nM (cpd-3) on CLK1/2, while showed more than 100 nM activity dose (both cpd-2 and cpd-3) on SRPK1/2/3, separately.133 In comparison, the IC50 values of cpd-1 are 16 and 45 nM on CLK1 and CLK2; the IC50 values of SRPK1, -2, and -3 were calculated as 61, 75, and 10000 nM. Cpd-1, cpd-2, and cpd-3 significantly decreased endogenous phosphorylation of SR proteins and enlarged the nuclear speckles in MDA-MB-468 cells. Meanwhile, the inhibitors resulted in splicing alterations of RPS6KB1(S6K) and subsequently caused S6K protein depletion.133 Moreover, cpd-2 and cpd-3 showed considerable growth inhibition (GI50) values in different cancer cell lines: for GI50 of cpd-2, 3.0 μM on breast cancer (MDA-MB-468), 1.9 and 1.4 μM on NSCLC (A549 and NCI-H23) and 1.7, 2.2, 2.0 and 0.6 μM on colorectal cancer (COLO205, HCT116, SW620, and COLO320DM); for GI50 of cpd-3, 3.4 μM on breast cancer (MDA-MB-468), 2.6 and 2.2 μM on NSCLC (A549 and NCI-H23) and 2.1, 2.5, 2.9 and 1.5 μM on colorectal cancer (COLO205, HCT116, SW620, and COLO320DM). The data suggested that cpd compounds functioned as CLK inhibitors that exerted tumor growth inhibitory effects through splicing alterations.133

MU1210 is a potent inhibitor of CLKs with IC50 values of 8 nM for CLK1, 20 nM for CLK2, 12 nM for CLK4, and more than 3000 nM for CLK3; notably, off target against HIPKs and DYRKs were observed at relatively high IC50 concentration.134 MU1210 attenuated MCF-7 cell proliferation and showed IC50 of 4.6 μM in cell viability.134 However, the detailed biological functions and potential of MU1210 in cancer treatment are largely uncharacterized.

Indazole1 is a novel potent in-house inhibitor of CLK2 with an IC50 of 10 nM that was identified by in silico screening.63 Indazole1 also potently inhibited CLK1, CLK3, CLK4, and DYRK1A in vitro with the IC50 values of 12 nM, 2250 nM, 12 nM, and 73 nM, respectively. Of note, the data demonstrated that Indazole1 tended to be a more potent CLKs inhibitor than TG003 by increasing the frequencies of micro-nucleated binucleates (MNBN) in a dose-dependent manner in primary human lymphocytes.63

KuWal151, a member of 3-Aryl-substituted 6,7-dihydropyrrolo[3,4-g]indol-8(1H)-ones class, was identified as an inhibitor of CLK1, -2 and -4 with the IC50 values for CLK1/2/4 of 88 nM, 510 nM and 28 nM, respectively.135 Interestingly, this compound is inactive against CLK3, DYRK1A/B, and DYRK2.135 KuWal151 showed less than 500 nM potency in more than 50 cancer cell lines, especially in the MDA-MB-435 cell line (GI50 = 72.4 nM) which exhibited heightened expression of CLK1.135 UACC-257 cells showed the lowest CLK1 expression levels and were least sensitive to KuWal151 application with a GI value over 50 μM.135 The sensitivities of different cancer cell lines with distinct expression levels of SPF45, an essential substrate of CLK1, to KuWal151 were determined. The results indicated that cells (HCT-116, HCT-15, HT-29, KM12, MCF-7) with increased SPF45 levels were dramatically suppressed by KuWal151. In contrast, OVCAR-8, HOP-92, and MDA-MB-431 were less sensitive to the compound under similar conditions, further proving the correlation between KuWal151 and CLK1.135 Thus, KuWal151 might be a potential compound or suitable lead compound for the synthesis of anti-cancer agents targeting CLKs.

GPS167 is a novel CLKs inhibitor that originated from a class of compounds to interrupt HIV replication. GPS167 was subsequently identified to exhibit approximately 50% inhibition on splicing response at 2 μM.45 A 32P-kinase assay revealed that GPS167 decreased the CLKs-mediated phosphorylation of SRSF10, but not by DRPK1 and SRPK, in a dose-dependent manner. The Colo205, SW620, and HCT116 cancer cell lines were most sensitive to GPS167 as evidenced by the results of CellTox-Green assays. However, the compound showed less cytotoxicity on CRL-1831, CRL-1790, and Caco-2 normal colonocyte cell lines.45 Intriguingly, the inhibition of GPS167 on cell growth and viability was discovered to be p53-dependent.45 Collectively, GPS167 is a novel inhibitor of CLKs which impairs cell proliferation and organoids growth of human CRC cells via interrupting SRSF10 phosphorylation.45

Silmitasertib (CX-4945) is a dual inhibitor of CLK2 and CK2. CX-4945 strongly inhibited CK2 with an IC50 value of 1 nM against CK2α and CK2α‘; however, it also had a high affinity for CLKs and DYRK1A.136 The reported IC50 value of CX-4945 on CLK1 is 82.3 nM, on CLK2 is 3.8 nM, on CLK3 is 90 nM, and more than 1000 nM on SRPK1 and SRPK2.136 CX-4945 was shown to be a CLK2 ATP-competitive inhibitor capable of modulating SR protein phosphorylation with an IC50 concentration ranging between 3 to 90 nM.136 The phosphorylation status of SRSF4, SRSF6, SRSF5, and SRSF1 were profoundly decreased in 293-T cells following CX-4945 treatment, indicating that CLKs are targets of the inhibitor.136 Surprisingly, CX-4945 showed a greater inhibitory effect than TG003, with a comparable effect on SR protein phosphorylation observed at 1 µM CX-4945 and 10 µM TG-003, suggesting the potential for treating diseases characterized by splicing dysregulation.136 The efficacy of CX-4945 has been demonstrated in a broad range of human malignancies. CX-4945 inhibited cell proliferation and induced caspase-3 independent non-autophagic cell death in CCA Cells137; CX-4945 suppressed TGF-β1-induced migration and invasion in human A549 cancer cells,138 and arrested cell cycle in vitro Moreover, CX-4945 inhibited BT-474 and BxPC-3 xenograft tumor growth in vivo in a dose-dependent way.139 Moreover, a synergistic effect was observed when CX-4945 was combined with bortezomib to treat acute lymphoblastic leukemia140 and multiple myeloma and mantle cell lymphoma cell lines.141 Increased therapeutic effects were observed when CX-4945 cooperated with dasatinib in ovarian cancer;142 cooperated with cisplatin and gemcitabine in holangiocarcinoma143,144 and with temozolomide in GBM.144,145

A phase I/II clinical trial (NCT03904862) of CX-4945 that aims to test the safety and tolerability in individuals with recurrent medulloblastoma is currently recruiting patients. Another phase I clinical trial (NCT03897036) to evaluate the treatment duration and pharmacodynamics of CX-4945 in basal cell carcinoma (BCC) is also currently recruiting volunteers. Additionally, a combination study of CX-4945 with ATM inhibitors (Sunitinib, Pazopanib, and Temsirolimus) in kidney cancer (NCT03571438) which aims to evaluate the therapeutic potential of the compounds in clinical treatment is currently ongoing. A recently completed phase I/II clinical trial (NCT02128282) estimated the safety and tolerability of increasing doses of CX-4945 in combination with gemcitabine plus cisplatin to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D) in the frontline treatment of patients with cholangiocarcinoma. 200 mg CX-4945 combined with 25 mg/m.sq. cisplatin or 1,000 mg/m.sq. gemcitabine was adopted in MTD and RP2D estimation. Unfortunately, the results are presently unavailable to the public. Additional experiments and clinical trials are currently scheduled to assess the therapeutic potential of CX-4945 in cancer treatment.

CC-671 is a dual inhibitor of CLK2 and Monopolar spindle 1 (Mps1, also named TTK).146 Seven kinases showed over 80% inhibition by CC-671 across a 255 kinases panel. TTK and CLK2 activities were potently suppressed of the seven identified kinases with IC50 values of 5 nM and 6 nM, respectively.146 Other kinases, such as CLK1 or DYRKs, were also inhibited by CC-671 with different IC50 values.146 Interestingly, results from a series of ActivX KiNative™ profiling assays indicated that CLK2 was inhibited in vitro by CC-671 with an IC50 of 15 nM; however, TTK was not inhibited.146 Furthermore, treatment of different breast cancer cell lines with CC-671 showed that luminal BC cells were more sensitive to CC-671 treatment versus TNBC cells.146

Thiophene 48 is a dual DYRK/CLK1 inhibitor that was synthesized based on the natural molecule harmine.147 Thiophene 48 showed potent activity with IC50 values of 110 nM, 100 nM, 70 nM, and 40 nM on CLK1, DYRK1A, DYRK1B, and DYRK2, respectively. Moreover, the compound was found to have a 75-fold, 3-fold, and 2-fold better inhibitory activity against DYRK2, DYRK1B, and CLK1 compared to the reference compound harmine.147 1 μM Thiophene 48 significantly induced cell apoptosis in U2OS osteosarcoma cells by increasing the ratio of caspase 3/7. However, Thiophene 48 showed no cytotoxicity at 5 μM on V79 hamster lung fibroblasts while the same concentration of Harmine significantly inhibited cell growth.147

Leucettine L41 is a dual inhibitor of CLK1/4 and DYRKs. Leucettine L41 was modified by using Leucettamine B as an inhibitory scaffold, and was shown to co-crystallized with DYRK1A, DYRK2, CLK3, PIM1, and GSK-3β.148,149 Leucettine L41 exhibited potent inhibition on DYRK1A, DYRK1B, and DYRK2 with IC50 values of 60, 44, and 73 nM, respectively. However, the IC50 values with respect to CLKs are much higher.148 Compared to the effect of leucettamine B, the inhibitory activities of L41 were significantly increased against DYRKs, CLK1, and CLK4; however, the IC50 with respect to CLK3 was obvious increased from 1.8 nM to more than 10 μM, suggesting that CLK1/4 may also be ideal targets of L41.148 The study further indicated that L41 displayed a neuroprotective role in glutamate-induced HT22 cell death.148 Moreover, Leucettine L41 decreased the phosphorylation of SRp75 in HMEC-1 cells. In addition, a CLK1 minigene transgenic model in Hela cells indicated that L41 treatment significantly elevated the percentage of exon inclusion of CLK1 itself.150

More compounds have been shown to inhibit CLKs activities and/or other CMGC kinases; however, detailed molecular mechanisms and in vivo experimental evidence are currently sparce. For example: Compound 3A5,151 ML315,152 SRI-29329,153 ML167,154 ML106,155 and BM07114156 still lack the pre-clinical data to support their anti-diseases efficiency. The constant efforts that uncover the underlying potential of CLKs inhibitors to prevent various diseases will pave the path to drug development and facilitate the progress of diseases treatment.

Conclusions and future perspectives

Protein kinases, which phosphorylate specific substrate moieties, play critical roles in cell growth and differentiation. Substrate phosphorylation by kinases controls diverse cellular processes.157 Abnormal expression or dysfunction of protein kinases lead to many human diseases, including cancer. Many protein kinases are closely related to human diseases, for example, AURKA,158 AKT,159 CDK12,160 CDK15,161 LIMK,162 CLKs,163 AMPK,164 and p38 MAPK.165

CLKs participate in the phosphorylation of key proteins that regulate cellular metabolism and various signaling pathways.133,166 Irregular expression of CLKs and the dysregulation of alternative splicing have been identified in several human diseases; therefore, CLKs have emerged as a new class of disease hallmarks.167–169 Accumulating evidence has revealed the importance of CLKs in various physiological processes such as Duchenne muscular dystrophy, Alzheimer’s disease, and cancer. However, there are still limitations in the current understanding of CLKs. Firstly, the relationship between CLKs, immunotherapy, and the tumor microenvironment is currently unknown. Next, animal disease models, including CLKs conditional knockout or in situ disease models, are needed to fully understand the importance of CLKs in disease occurrence and development. Given the recent discovery showing that oxidation of the Met307 residue of CLK4 disrupted its kinase activity,126 more studies should be carried out to explore posttranslational modifications able to regulate CLKs function and expression. Moreover, the Q607R mutation within the CLK3 kinase domain enhanced c-Myc activity in promoting CCA,124 indicating the importance of CLKs somatic mutations in human diseases. Therefore, a mutation map of different CLKs detailing the functional consequences of specific mutations will contribute to explore the underlying molecular mechanism of CLKs. Therefore, continued investigation of CLKs functionality using high throughput sequencing and animal models are required to foster a more complete understanding of CLKs in human diseases occurrence and progression.

Due to the essential role of CLKs in human diseases, significant efforts have been made to study CLKs inhibitors using kinase screening technologies and pharmacological approaches. Most inhibitors have been well studied and have shown satisfactory anti-neurodegeneration, anti-inflammation, anti-viral, and anti-cancer effects by inhibiting the expression and activities of CLKs. However, there are still challenges associated with current CLKs inhibitors, and efforts can be made to achieve the following goals for disease therapeutics: 1) Targeted inhibition of specific CLKs for precision therapy. Most small molecular CLKs targeting drugs are broad-spectrum inhibitors, thus, specific inhibitors able to target CLK1, -2, -3, or -4 are needed to achieve greater therapeutic effect to reach a more precision therapy. 2) Development of pan-CLKs inhibitors to achieve heightened anti-cancer effects. The dysfunction and irregular expression of different CLKs members are concomitant in various human diseases, thus, the improvement of pan-CLKs inhibitors can help to maximize the treatment efficacy and benefit more patients in the clinic. 3) Enhance the specificity and selectivity of inhibitors to CLKs compared with other homologous CMGC family proteins through structural optimization. Many CLKs inhibitors show slight or strong off-target effects on other homologous kinases, such as, DYRKs and SRPKs. 4) Combination therapies of CLKs inhibitors with other compounds to achieve synergistic effects in the treatment of various diseases. Aiko et al. noted that treatment with CLK-IN-T3 in combination with the Bcl-xL/Bcl-2 inhibitor ABT-263 synergistically induced caspase 3/7-dependent apoptosis in A2780 and HCT116 cells compared to CLK-IN-T3 treatment alone.132 Meanwhile, E7107, an SF3b-targeting splicing modulator, synergistically enhanced apoptosis in NSCLC cell lines when combined with ABT-263.170 These findings indicate that the combination strategy of targeting CLKs with other inhibitors is an appropriate splicing molecular-based approach for future clinical development. It is noteworthy that certain CLKs inhibitors were recognized as ideal lead compounds for structural optimization to obtain more specific CLKs inhibitors. Moreover, a genetic function algorithm support vector regression (GFA-SVR)171 and ligand- or structure-based drug optimization172,173 provided predictive models and effective methods for screening and optimizing of the potential of CLKs inhibitors. Nonetheless, research on CLKs-based therapy is still in the initial stage; the cognition and development of CLKs inhibitors will undoubtedly progress upon more in-depth investigation.

In conclusion, CLKs facilitate biological processes through the phosphorylation or modulation of their downstream targets in a splicing or non-splicing-dependent manner. Changes in CLKs activity or expression level are closely related to pathological processes. CLKs inhibitors have shown significant therapeutic effects in various human diseases including neurodegenerative diseases, inflammatory diseases, viral replication, and cancer. To our knowledge, most of the compounds discussed in this review satisfy the criteria for chemical biology probes and have excellent prospects for the development of novel medicines. Given the essential role of CLKs in various human diseases, it can be expected that targeting CLK kinases may prove clinically beneficial in the future.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 82002620, No. 81972839, NO. 8207112153) and the Science and Technology Project of Henan Province (No. 212102310698, NO. 222102310102).

Author contributions

All authors made substantial contributions to the review. M.Q.S and L.P.P organized and wrote this review, M.M.Z and Y.Z.Q collected the data, K.V.L checked the language and corresponding author Z.G.D provided editorial assistance. All authors read and approved the final manuscript. All authors have read and approved the article.

Competing interests

The authors declare no competing interests.

Related links: The TCGA database: https://portal.gdc.cancer.gov/. Assistant for clinical bioinformatics: https://www.aclbi.com/static/index.html#/. Figdraw: https://www.figdraw.com/static/index.html#/.
==== Refs
References

1. Myers MP Murphy MB Landreth G The dual-specificity CLK kinase induces neuronal differentiation of PC12 cells Mol. Cell Biol. 1994 14 6954 6961 7935412
Myers, M. P., Murphy, M. B. & Landreth, G. The dual-specificity CLK kinase induces neuronal differentiation of PC12 cells. Mol. Cell Biol. 14, 6954–6961 (1994).7935412
2. Petsalaki E Zachos G Clks 1, 2 and 4 prevent chromatin breakage by regulating the Aurora B-dependent abscission checkpoint Nat. Commun. 2016 7 11451 10.1038/ncomms11451 27126587
Petsalaki, E. & Zachos, G. Clks 1, 2 and 4 prevent chromatin breakage by regulating the Aurora B-dependent abscission checkpoint. Nat. Commun. 7, 11451 (2016).27126587 10.1038/ncomms11451
3. Bullock AN Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation Structure 2009 17 352 362 10.1016/j.str.2008.12.023 19278650
Bullock, A. N. et al. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure 17, 352–362 (2009).19278650 10.1016/j.str.2008.12.023
4. Jain P Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer’s disease Curr. Drug Targets 2014 15 539 550 10.2174/1389450115666140226112321 24568585
Jain, P. et al. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer’s disease. Curr. Drug Targets 15, 539–550 (2014).24568585 10.2174/1389450115666140226112321
5. Jiang K Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid Endocrinology 2009 150 2087 2097 10.1210/en.2008-0818 19116344
Jiang, K. et al. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid. Endocrinology 150, 2087–2097 (2009).19116344 10.1210/en.2008-0818
6. Ballou LM Luther H Thomas G MAP2 kinase and 70K S6 kinase lie on distinct signalling pathways Nature 1991 349 348 350 10.1038/349348a0 1702881
Ballou, L. M., Luther, H. & Thomas, G. MAP2 kinase and 70K S6 kinase lie on distinct signalling pathways. Nature 349, 348–350 (1991).1702881 10.1038/349348a0
7. Yun B Farkas R Lee K Rabinow L The Doa locus encodes a member of a new protein kinase family and is essential for eye and embryonic development in Drosophila melanogaster Genes Dev. 1994 8 1160 1173 10.1101/gad.8.10.1160 7926721
Yun, B., Farkas, R., Lee, K. & Rabinow, L. The Doa locus encodes a member of a new protein kinase family and is essential for eye and embryonic development in Drosophila melanogaster. Genes Dev. 8, 1160–1173 (1994).7926721 10.1101/gad.8.10.1160
8. Prasad J Colwill K Pawson T Manley JL The protein kinase Clk/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing Mol. Cell Biol. 1999 19 6991 7000 10.1128/MCB.19.10.6991 10490636
Prasad, J., Colwill, K., Pawson, T. & Manley, J. L. The protein kinase Clk/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing. Mol. Cell Biol. 19, 6991–7000 (1999).10490636 10.1128/MCB.19.10.6991
9. Colwill K The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution Embo. j. 1996 15 265 275 10.1002/j.1460-2075.1996.tb00357.x 8617202
Colwill, K. et al. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. Embo. j. 15, 265–275 (1996).8617202 10.1002/j.1460-2075.1996.tb00357.x
10. Prasad J Manley JL Regulation and substrate specificity of the SR protein kinase Clk/Sty Mol. Cell Biol. 2003 23 4139 4149 10.1128/MCB.23.12.4139-4149.2003 12773558
Prasad, J. & Manley, J. L. Regulation and substrate specificity of the SR protein kinase Clk/Sty. Mol. Cell Biol. 23, 4139–4149 (2003).12773558 10.1128/MCB.23.12.4139-4149.2003
11. ElHady AK Abdel-Halim M Abadi AH Engel M Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins J. Med. Chem. 2017 60 5377 5391 10.1021/acs.jmedchem.6b01915 28561591
ElHady, A. K., Abdel-Halim, M., Abadi, A. H. & Engel, M. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins. J. Med. Chem. 60, 5377–5391 (2017).28561591 10.1021/acs.jmedchem.6b01915
12. Martín Moyano, P., Němec, V. & Paruch, K. Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential. Int. J. Mol. Sci. 21, 7549 (2020).
13. Nayler O Stamm S Ullrich A Characterization and comparison of four serine- and arginine-rich (SR) protein kinases Biochem. J. 1997 326 Pt 3 693 700 10.1042/bj3260693 9307018
Nayler, O., Stamm, S. & Ullrich, A. Characterization and comparison of four serine- and arginine-rich (SR) protein kinases. Biochem. J. 326(Pt 3), 693–700 (1997).9307018 10.1042/bj3260693
14. Aubol BE Release of SR Proteins from CLK1 by SRPK1: A Symbiotic Kinase System for Phosphorylation Control of Pre-mRNA Splicing Mol. Cell 2016 63 218 228 10.1016/j.molcel.2016.05.034 27397683
Aubol, B. E. et al. Release of SR Proteins from CLK1 by SRPK1: A Symbiotic Kinase System for Phosphorylation Control of Pre-mRNA Splicing. Mol. Cell 63, 218–228 (2016).27397683 10.1016/j.molcel.2016.05.034
15. Zhou Z Fu XD Regulation of splicing by SR proteins and SR protein-specific kinases Chromosoma 2013 122 191 207 10.1007/s00412-013-0407-z 23525660
Zhou, Z. & Fu, X. D. Regulation of splicing by SR proteins and SR protein-specific kinases. Chromosoma 122, 191–207 (2013).23525660 10.1007/s00412-013-0407-z
16. Huang Y Gattoni R Stévenin J Steitz JA SR splicing factors serve as adapter proteins for TAP-dependent mRNA export Mol. Cell 2003 11 837 843 10.1016/S1097-2765(03)00089-3 12667464
Huang, Y., Gattoni, R., Stévenin, J. & Steitz, J. A. SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. Mol. Cell 11, 837–843 (2003).12667464 10.1016/S1097-2765(03)00089-3
17. Lee K Du C Horn M Rabinow L Activity and autophosphorylation of LAMMER protein kinases J. Biol. Chem. 1996 271 27299 27303 10.1074/jbc.271.44.27299 8910305
Lee, K., Du, C., Horn, M. & Rabinow, L. Activity and autophosphorylation of LAMMER protein kinases. J. Biol. Chem. 271, 27299–27303 (1996).8910305 10.1074/jbc.271.44.27299
18. Xie SH Molecular cloning, expression, and chromosomal mapping of the porcine CDC-2-like kinase 1 (CLK1) gene Biochem. Genet. 2009 47 266 275 10.1007/s10528-009-9226-6 19194796
Xie, S. H. et al. Molecular cloning, expression, and chromosomal mapping of the porcine CDC-2-like kinase 1 (CLK1) gene. Biochem. Genet. 47, 266–275 (2009).19194796 10.1007/s10528-009-9226-6
19. Colwill K SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors J. Biol. Chem. 1996 271 24569 24575 10.1074/jbc.271.40.24569 8798720
Colwill, K. et al. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors. J. Biol. Chem. 271, 24569–24575 (1996).8798720 10.1074/jbc.271.40.24569
20. Keshwani MM Conserved proline-directed phosphorylation regulates SR protein conformation and splicing function Biochem. J. 2015 466 311 322 10.1042/BJ20141373 25529026
Keshwani, M. M. et al. Conserved proline-directed phosphorylation regulates SR protein conformation and splicing function. Biochem. J. 466, 311–322 (2015).25529026 10.1042/BJ20141373
21. Czubaty A Piekiełko-Witkowska A Protein kinases that phosphorylate splicing factors: Roles in cancer development, progression and possible therapeutic options Int J. Biochem. Cell Biol. 2017 91 102 115 10.1016/j.biocel.2017.05.024 28552434
Czubaty, A. & Piekiełko-Witkowska, A. Protein kinases that phosphorylate splicing factors: Roles in cancer development, progression and possible therapeutic options. Int J. Biochem. Cell Biol. 91, 102–115 (2017).28552434 10.1016/j.biocel.2017.05.024
22. Tabata M Cdc2-like kinase 2 suppresses hepatic fatty acid oxidation and ketogenesis through disruption of the PGC-1α and MED1 complex Diabetes 2014 63 1519 1532 10.2337/db13-1304 24458359
Tabata, M. et al. Cdc2-like kinase 2 suppresses hepatic fatty acid oxidation and ketogenesis through disruption of the PGC-1α and MED1 complex. Diabetes 63, 1519–1532 (2014).24458359 10.2337/db13-1304
23. Menegay H Moeslein F Landreth G The dual specificity protein kinase CLK3 is abundantly expressed in mature mouse spermatozoa Exp. Cell Res 1999 253 463 473 10.1006/excr.1999.4655 10585269
Menegay, H., Moeslein, F. & Landreth, G. The dual specificity protein kinase CLK3 is abundantly expressed in mature mouse spermatozoa. Exp. Cell Res. 253, 463–473 (1999).10585269 10.1006/excr.1999.4655
24. Ninomiya K LncRNA-dependent nuclear stress bodies promote intron retention through SR protein phosphorylation Embo j. 2020 39 e102729 10.15252/embj.2019102729 31782550
Ninomiya, K. et al. LncRNA-dependent nuclear stress bodies promote intron retention through SR protein phosphorylation. Embo j. 39, e102729 (2020).31782550 10.15252/embj.2019102729
25. Aubol BE N-terminus of the protein kinase CLK1 induces SR protein hyperphosphorylation Biochem. J. 2014 462 143 152 10.1042/BJ20140494 24869919
Aubol, B. E. et al. N-terminus of the protein kinase CLK1 induces SR protein hyperphosphorylation. Biochem. J. 462, 143–152 (2014).24869919 10.1042/BJ20140494
26. Lee JY Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945 Biomed. Res. Int. 2019 2019 6125068 10.1155/2019/6125068 31531359
Lee, J. Y. et al. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945. Biomed. Res. Int. 2019, 6125068 (2019).31531359 10.1155/2019/6125068
27. Schröder M DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity J. Med. Chem. 2020 63 10224 10234 10.1021/acs.jmedchem.0c00898 32787076
Schröder, M. et al. DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity. J. Med. Chem. 63, 10224–10234 (2020).32787076 10.1021/acs.jmedchem.0c00898
28. Němec V Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway Angew. Chem. Int. Ed. Engl. 2019 58 1062 1066 10.1002/anie.201810312 30569600
Němec, V. et al. Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. Angew. Chem. Int. Ed. Engl. 58, 1062–1066 (2019).30569600 10.1002/anie.201810312
29. Liu Y Noncoding RNAs regulate alternative splicing in Cancer J. Exp. Clin. Cancer Res 2021 40 11 10.1186/s13046-020-01798-2 33407694
Liu, Y. et al. Noncoding RNAs regulate alternative splicing in Cancer. J. Exp. Clin. Cancer Res. 40, 11 (2021).33407694 10.1186/s13046-020-01798-2
30. Song X Zeng Z Wei H Wang Z Alternative splicing in cancers: From aberrant regulation to new therapeutics Semin Cell Dev. Biol. 2018 75 13 22 10.1016/j.semcdb.2017.09.018 28919308
Song, X., Zeng, Z., Wei, H. & Wang, Z. Alternative splicing in cancers: From aberrant regulation to new therapeutics. Semin Cell Dev. Biol. 75, 13–22 (2018).28919308 10.1016/j.semcdb.2017.09.018
31. Zhang Y Qian J Gu C Yang Y Alternative splicing and cancer: a systematic review Signal Transduct. Target Ther. 2021 6 78 10.1038/s41392-021-00486-7 33623018
Zhang, Y., Qian, J., Gu, C. & Yang, Y. Alternative splicing and cancer: a systematic review. Signal Transduct. Target Ther. 6, 78 (2021).33623018 10.1038/s41392-021-00486-7
32. Ule J Blencowe BJ Alternative Splicing Regulatory Networks: Functions, Mechanisms, and Evolution Mol. Cell 2019 76 329 345 10.1016/j.molcel.2019.09.017 31626751
Ule, J. & Blencowe, B. J. Alternative Splicing Regulatory Networks: Functions, Mechanisms, and Evolution. Mol. Cell 76, 329–345 (2019).31626751 10.1016/j.molcel.2019.09.017
33. Shkreta L Delannoy A Salvetti A Chabot B SRSF10: an atypical splicing regulator with critical roles in stress response, organ development, and viral replication Rna 2021 27 1302 1317 10.1261/rna.078879.121 34315816
Shkreta, L., Delannoy, A., Salvetti, A. & Chabot, B. SRSF10: an atypical splicing regulator with critical roles in stress response, organ development, and viral replication. Rna 27, 1302–1317 (2021).34315816 10.1261/rna.078879.121
34. Kędzierska H Piekiełko-Witkowska A Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer Cancer Lett. 2017 396 53 65 10.1016/j.canlet.2017.03.013 28315432
Kędzierska, H. & Piekiełko-Witkowska, A. Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. Cancer Lett. 396, 53–65 (2017).28315432 10.1016/j.canlet.2017.03.013
35. Bonnal SC López-Oreja I Valcárcel J Roles and mechanisms of alternative splicing in cancer - implications for care Nat. Rev. Clin. Oncol. 2020 17 457 474 10.1038/s41571-020-0350-x 32303702
Bonnal, S. C., López-Oreja, I. & Valcárcel, J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat. Rev. Clin. Oncol. 17, 457–474 (2020).32303702 10.1038/s41571-020-0350-x
36. Jeong S SR Proteins: Binders, Regulators, and Connectors of RNA Mol. Cells 2017 40 1 9 10.14348/molcells.2017.2319 28152302
Jeong, S. SR Proteins: Binders, Regulators, and Connectors of RNA. Mol. Cells 40, 1–9 (2017).28152302 10.14348/molcells.2017.2319
37. Martinez-Montiel, N. et al. Alternative Splicing as a Target for Cancer Treatment. Int. J. Mol. Sci. 19, 819 (2018).
38. Lee Y Rio DC Mechanisms and Regulation of Alternative Pre-mRNA Splicing Annu. Rev. Biochem 2015 84 291 323 10.1146/annurev-biochem-060614-034316 25784052
Lee, Y. & Rio, D. C. Mechanisms and Regulation of Alternative Pre-mRNA Splicing. Annu. Rev. Biochem. 84, 291–323 (2015).25784052 10.1146/annurev-biochem-060614-034316
39. Das S Krainer AR Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer Mol. Cancer Res 2014 12 1195 1204 10.1158/1541-7786.MCR-14-0131 24807918
Das, S. & Krainer, A. R. Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer. Mol. Cancer Res 12, 1195–1204 (2014).24807918 10.1158/1541-7786.MCR-14-0131
40. Babu N Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer Gastric Cancer 2020 23 796 810 10.1007/s10120-020-01062-8 32333232
Babu, N. et al. Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer. Gastric Cancer 23, 796–810 (2020).32333232 10.1007/s10120-020-01062-8
41. Anczuków O The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation Nat. Struct. Mol. Biol. 2012 19 220 228 10.1038/nsmb.2207 22245967
Anczuków, O. et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 19, 220–228 (2012).22245967 10.1038/nsmb.2207
42. Yoshida T CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer Cancer Res 2015 75 1516 1526 10.1158/0008-5472.CAN-14-2443 25670169
Yoshida, T. et al. CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. Cancer Res. 75, 1516–1526 (2015).25670169 10.1158/0008-5472.CAN-14-2443
43. Cesana M A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development Cell Stem Cell 2018 22 575 588 10.1016/j.stem.2018.03.012 29625070
Cesana, M. et al. A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development. Cell Stem Cell 22, 575–588 (2018). e577.29625070 10.1016/j.stem.2018.03.012
44. Chen S CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer J. Hematol. Oncol. 2021 14 60 10.1186/s13045-021-01072-8 33849617
Chen, S. et al. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. J. Hematol. Oncol. 14, 60 (2021).33849617 10.1186/s13045-021-01072-8
45. Sohail M A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells NAR Cancer 2021 3 zcab019 10.1093/narcan/zcab019 34316707
Sohail, M. et al. A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells. NAR Cancer 3, zcab019 (2021).34316707 10.1093/narcan/zcab019
46. Liu Y Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion Nucleic Acids Res 2013 41 4949 4962 10.1093/nar/gkt170 23519612
Liu, Y. et al. Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Res. 41, 4949–4962 (2013).23519612 10.1093/nar/gkt170
47. Uzor S Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention Gene 2018 670 46 54 10.1016/j.gene.2018.05.095 29802995
Uzor, S. et al. Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention. Gene 670, 46–54 (2018).29802995 10.1016/j.gene.2018.05.095
48. Aubol, B. E. et al. CLK1 reorganizes the splicing factor U1-70K for early spliceosomal protein assembly. Proc. Natl. Acad. Sci. USA. 118, e2018251118 (2021).
49. Moeslein FM Myers MP Landreth GE The CLK family kinases, CLK1 and CLK2, phosphorylate and activate the tyrosine phosphatase, PTP-1B J. Biol. Chem. 1999 274 26697 26704 10.1074/jbc.274.38.26697 10480872
Moeslein, F. M., Myers, M. P. & Landreth, G. E. The CLK family kinases, CLK1 and CLK2, phosphorylate and activate the tyrosine phosphatase, PTP-1B. J. Biol. Chem. 274, 26697–26704 (1999).10480872 10.1074/jbc.274.38.26697
50. Rodgers JT Haas W Gygi SP Puigserver P Cdc2-like kinase 2 is an insulin-regulated suppressor of hepatic gluconeogenesis Cell Metab. 2010 11 23 34 10.1016/j.cmet.2009.11.006 20074525
Rodgers, J. T., Haas, W., Gygi, S. P. & Puigserver, P. Cdc2-like kinase 2 is an insulin-regulated suppressor of hepatic gluconeogenesis. Cell Metab. 11, 23–34 (2010).20074525 10.1016/j.cmet.2009.11.006
51. Rodgers JT Vogel RO Puigserver P Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt Mol. Cell 2011 41 471 479 10.1016/j.molcel.2011.02.007 21329884
Rodgers, J. T., Vogel, R. O. & Puigserver, P. Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. Mol. Cell 41, 471–479 (2011).21329884 10.1016/j.molcel.2011.02.007
52. Nam SY Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls cell survival after ionizing radiation J. Biol. Chem. 2010 285 31157 31163 10.1074/jbc.M110.122044 20682768
Nam, S. Y. et al. Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls cell survival after ionizing radiation. J. Biol. Chem. 285, 31157–31163 (2010).20682768 10.1074/jbc.M110.122044
53. Li P Clk/STY (cdc2-like kinase 1) and Akt regulate alternative splicing and adipogenesis in 3T3-L1 pre-adipocytes PLoS One 2013 8 e53268 10.1371/journal.pone.0053268 23308182
Li, P. et al. Clk/STY (cdc2-like kinase 1) and Akt regulate alternative splicing and adipogenesis in 3T3-L1 pre-adipocytes. PLoS One 8, e53268 (2013).23308182 10.1371/journal.pone.0053268
54. Nayler O Schnorrer F Stamm S Ullrich A The cellular localization of the murine serine/arginine-rich protein kinase CLK2 is regulated by serine 141 autophosphorylation J. Biol. Chem. 1998 273 34341 34348 10.1074/jbc.273.51.34341 9852100
Nayler, O., Schnorrer, F., Stamm, S. & Ullrich, A. The cellular localization of the murine serine/arginine-rich protein kinase CLK2 is regulated by serine 141 autophosphorylation. J. Biol. Chem. 273, 34341–34348 (1998).9852100 10.1074/jbc.273.51.34341
55. Park SY Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors Am. J. Cancer Res 2020 10 3765 3783 33294266
Park, S. Y. et al. Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. Am. J. Cancer Res. 10, 3765–3783 (2020).33294266
56. Huang J CDC-like kinase 4 deficiency contributes to pathological cardiac hypertrophy by modulating NEXN phosphorylation Nat. Commun. 2022 13 4433 10.1038/s41467-022-31996-9 35907876
Huang, J. et al. CDC-like kinase 4 deficiency contributes to pathological cardiac hypertrophy by modulating NEXN phosphorylation. Nat. Commun. 13, 4433 (2022).35907876 10.1038/s41467-022-31996-9
57. Capra M Frequent alterations in the expression of serine/threonine kinases in human cancers Cancer Res 2006 66 8147 8154 10.1158/0008-5472.CAN-05-3489 16912193
Capra, M. et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res. 66, 8147–8154 (2006).16912193 10.1158/0008-5472.CAN-05-3489
58. ElHady, A. K. et al. An overview of cdc2-like kinase 1 (Clk1) inhibitors and their therapeutic indications. Med. Res. Rev. 43, 343–398 (2022).
59. Shi J Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease J. Biol. Chem. 2011 286 14639 14648 10.1074/jbc.M110.204453 21367856
Shi, J. et al. Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease. J. Biol. Chem. 286, 14639–14648 (2011).21367856 10.1074/jbc.M110.204453
60. Glatz DC The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer’s disease J. Neurochem. 2006 96 635 644 10.1111/j.1471-4159.2005.03552.x 16371011
Glatz, D. C. et al. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer’s disease. J. Neurochem. 96, 635–644 (2006).16371011 10.1111/j.1471-4159.2005.03552.x
61. Kumar Jain A Unravelling the Selectivity of 6,7-Dimethyl Quinoxaline Analogs for Kinase Inhibition: An Insight towards the Development of Alzheimer’s Therapeutics Chem. Biodivers. 2021 18 e2100364 10.1002/cbdv.202100364 34486216
Kumar Jain, A. et al. Unravelling the Selectivity of 6,7-Dimethyl Quinoxaline Analogs for Kinase Inhibition: An Insight towards the Development of Alzheimer’s Therapeutics. Chem. Biodivers. 18, e2100364 (2021).34486216 10.1002/cbdv.202100364
62. Hartmann AM Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors Mol. Cell Neurosci. 2001 18 80 90 10.1006/mcne.2001.1000 11461155
Hartmann, A. M. et al. Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors. Mol. Cell Neurosci. 18, 80–90 (2001).11461155 10.1006/mcne.2001.1000
63. Kallen J X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome ChemMedChem 2018 13 1997 2007 10.1002/cmdc.201800344 29985556
Kallen, J. et al. X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome. ChemMedChem 13, 1997–2007 (2018).29985556 10.1002/cmdc.201800344
64. Bidinosti M CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency Science 2016 351 1199 1203 10.1126/science.aad5487 26847545
Bidinosti, M. et al. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency. Science 351, 1199–1203 (2016).26847545 10.1126/science.aad5487
65. Wood MJ Gait MJ Yin H RNA-targeted splice-correction therapy for neuromuscular disease Brain 2010 133 957 972 10.1093/brain/awq002 20150322
Wood, M. J., Gait, M. J. & Yin, H. RNA-targeted splice-correction therapy for neuromuscular disease. Brain 133, 957–972 (2010).20150322 10.1093/brain/awq002
66. Matsuo M Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy Brain Dev. 1996 18 167 172 10.1016/0387-7604(96)00007-1 8836495
Matsuo, M. Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. Brain Dev. 18, 167–172 (1996).8836495 10.1016/0387-7604(96)00007-1
67. Sako Y Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy Sci. Rep. 2017 7 46126 10.1038/srep46126 28555643
Sako, Y. et al. Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. Sci. Rep. 7, 46126 (2017).28555643 10.1038/srep46126
68. Nishida A Chemical treatment enhances skipping of a mutated exon in the dystrophin gene Nat. Commun. 2011 2 308 10.1038/ncomms1306 21556062
Nishida, A. et al. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat. Commun. 2, 308 (2011).21556062 10.1038/ncomms1306
69. Deshmukh V SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy J. Orthop. Res. 2021 39 2048 2061 10.1002/jor.24898 33104243
Deshmukh, V. et al. SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy. J. Orthop. Res. 39, 2048–2061 (2021).33104243 10.1002/jor.24898
70. Howell DS Pathogenesis of osteoarthritis Am. J. Med 1986 80 24 28 10.1016/0002-9343(86)90075-6 3010715
Howell, D. S. Pathogenesis of osteoarthritis. Am. J. Med. 80, 24–28 (1986).3010715 10.1016/0002-9343(86)90075-6
71. Deshmukh V Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment Osteoarthr. Cartil. 2019 27 1347 1360 10.1016/j.joca.2019.05.006
Deshmukh, V. et al. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthr. Cartil. 27, 1347–1360 (2019).10.1016/j.joca.2019.05.006
72. Luyten FP Tylzanowski P Lories RJ Wnt signaling and osteoarthritis Bone 2009 44 522 527 10.1016/j.bone.2008.12.006 19136083
Luyten, F. P., Tylzanowski, P. & Lories, R. J. Wnt signaling and osteoarthritis. Bone 44, 522–527 (2009).19136083 10.1016/j.bone.2008.12.006
73. Yazici Y Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial Arthritis Rheumatol. 2020 72 1694 1706 10.1002/art.41315 32432388
Yazici, Y. et al. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis Rheumatol. 72, 1694–1706 (2020).32432388 10.1002/art.41315
74. Yazici Y A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study Osteoarthr. Cartil. 2017 25 1598 1606 10.1016/j.joca.2017.07.006
Yazici, Y. et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthr. Cartil. 25, 1598–1606 (2017).10.1016/j.joca.2017.07.006
75. Tambiah JRS Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial Rheumatol. Ther. 2021 8 973 985 10.1007/s40744-021-00316-w 34101138
Tambiah, J. R. S. et al. Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial. Rheumatol. Ther. 8, 973–985 (2021).34101138 10.1007/s40744-021-00316-w
76. Tambiah JRS Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint Am. J. Sports Med 2022 50 630 636 10.1177/03635465211067201 35005990
Tambiah, J. R. S. et al. Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint. Am. J. Sports Med. 50, 630–636 (2022).35005990 10.1177/03635465211067201
77. Stoltzfus CM Madsen JM Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing Curr. HIV Res 2006 4 43 55 10.2174/157016206775197655 16454710
Stoltzfus, C. M. & Madsen, J. M. Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Curr. HIV Res. 4, 43–55 (2006).16454710 10.2174/157016206775197655
78. McLaren M Marsh K Cochrane A Modulating HIV-1 RNA processing and utilization Front. Biosci. 2008 13 5693 5707 10.2741/3110 18508616
McLaren, M., Marsh, K. & Cochrane, A. Modulating HIV-1 RNA processing and utilization. Front. Biosci. 13, 5693–5707 (2008).18508616 10.2741/3110
79. Fukuhara T Utilization of host SR protein kinases and RNA-splicing machinery during viral replication Proc. Natl Acad. Sci. USA 2006 103 11329 11333 10.1073/pnas.0604616103 16840555
Fukuhara, T. et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl Acad. Sci. USA 103, 11329–11333 (2006).16840555 10.1073/pnas.0604616103
80. Ryo A Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cells AIDS Res Hum. Retroviruses 2000 16 995 1005 10.1089/08892220050058416 10890361
Ryo, A. et al. Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cells. AIDS Res Hum. Retroviruses 16, 995–1005 (2000).10890361 10.1089/08892220050058416
81. Wong R Differential effect of CLK SR Kinases on HIV-1 gene expression: potential novel targets for therapy Retrovirology 2011 8 47 10.1186/1742-4690-8-47 21682887
Wong, R. et al. Differential effect of CLK SR Kinases on HIV-1 gene expression: potential novel targets for therapy. Retrovirology 8, 47 (2011).21682887 10.1186/1742-4690-8-47
82. Wilson CM Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025 J. Acquir Immune Defic. Syndr. 2004 35 138 143 10.1097/00126334-200402010-00006 14722445
Wilson, C. M. et al. Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025. J. Acquir Immune Defic. Syndr. 35, 138–143 (2004).14722445 10.1097/00126334-200402010-00006
83. Artarini A Regulation of influenza A virus mRNA splicing by CLK1 Antivir. Res 2019 168 187 196 10.1016/j.antiviral.2019.06.003 31176694
Artarini, A. et al. Regulation of influenza A virus mRNA splicing by CLK1. Antivir. Res. 168, 187–196 (2019).31176694 10.1016/j.antiviral.2019.06.003
84. An J A novel link of HLA locus to the regulation of immunity and infection: NFKBIL1 regulates alternative splicing of human immune-related genes and influenza virus M gene J. Autoimmun. 2013 47 25 33 10.1016/j.jaut.2013.07.010 23953137
An, J. et al. A novel link of HLA locus to the regulation of immunity and infection: NFKBIL1 regulates alternative splicing of human immune-related genes and influenza virus M gene. J. Autoimmun. 47, 25–33 (2013).23953137 10.1016/j.jaut.2013.07.010
85. Karlas A Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication Nature 2010 463 818 822 10.1038/nature08760 20081832
Karlas, A. et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463, 818–822 (2010).20081832 10.1038/nature08760
86. Zu M Drug Discovery of Host CLK1 Inhibitors for Influenza Treatment Molecules 2015 20 19735 19747 10.3390/molecules201119653 26540031
Zu, M. et al. Drug Discovery of Host CLK1 Inhibitors for Influenza Treatment. Molecules 20, 19735–19747 (2015).26540031 10.3390/molecules201119653
87. Li C Anti-influenza effect and action mechanisms of the chemical constituent gallocatechin-7-gallate from Pithecellobium clypearia Benth Acta Pharm. Sin. 2018 39 1913 1922 10.1038/s41401-018-0030-x
Li, C. et al. Anti-influenza effect and action mechanisms of the chemical constituent gallocatechin-7-gallate from Pithecellobium clypearia Benth. Acta Pharm. Sin. 39, 1913–1922 (2018).10.1038/s41401-018-0030-x
88. Krishnan MN RNA interference screen for human genes associated with West Nile virus infection Nature 2008 455 242 245 10.1038/nature07207 18690214
Krishnan, M. N. et al. RNA interference screen for human genes associated with West Nile virus infection. Nature 455, 242–245 (2008).18690214 10.1038/nature07207
89. Dekel N Expression, purification and crystallization of CLK1 kinase - A potential target for antiviral therapy Protein Expr. Purif. 2020 176 105742 10.1016/j.pep.2020.105742 32866611
Dekel, N. et al. Expression, purification and crystallization of CLK1 kinase - A potential target for antiviral therapy. Protein Expr. Purif. 176, 105742 (2020).32866611 10.1016/j.pep.2020.105742
90. Karlas A A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs Nat. Commun. 2016 7 11320 10.1038/ncomms11320 27177310
Karlas, A. et al. A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs. Nat. Commun. 7, 11320 (2016).27177310 10.1038/ncomms11320
91. Zhang Y Discovery of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors Bioorg. Med Chem. Lett. 2021 41 127881 10.1016/j.bmcl.2021.127881 33662541
Zhang, Y. et al. Discovery of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors. Bioorg. Med Chem. Lett. 41, 127881 (2021).33662541 10.1016/j.bmcl.2021.127881
92. Lee MS Role of islet β cell autophagy in the pathogenesis of diabetes Trends Endocrinol. Metab. 2014 25 620 627 10.1016/j.tem.2014.08.005 25242548
Lee, M. S. Role of islet β cell autophagy in the pathogenesis of diabetes. Trends Endocrinol. Metab. 25, 620–627 (2014).25242548 10.1016/j.tem.2014.08.005
93. Riahi Y Autophagy is a major regulator of beta cell insulin homeostasis Diabetologia 2016 59 1480 1491 10.1007/s00125-016-3868-9 26831301
Riahi, Y. et al. Autophagy is a major regulator of beta cell insulin homeostasis. Diabetologia 59, 1480–1491 (2016).26831301 10.1007/s00125-016-3868-9
94. Yamamoto K Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I Nature 2020 581 100 105 10.1038/s41586-020-2229-5 32376951
Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100–105 (2020).32376951 10.1038/s41586-020-2229-5
95. Matsuzawa-Ishimoto Y Hwang S Cadwell K Autophagy and Inflammation Annu. Rev. Immunol. 2018 36 73 101 10.1146/annurev-immunol-042617-053253 29144836
Matsuzawa-Ishimoto, Y., Hwang, S. & Cadwell, K. Autophagy and Inflammation. Annu. Rev. Immunol. 36, 73–101 (2018).29144836 10.1146/annurev-immunol-042617-053253
96. Deretic V Autophagy in inflammation, infection, and immunometabolism Immunity 2021 54 437 453 10.1016/j.immuni.2021.01.018 33691134
Deretic, V. Autophagy in inflammation, infection, and immunometabolism. Immunity 54, 437–453 (2021).33691134 10.1016/j.immuni.2021.01.018
97. Racanelli AC Kikkers SA Choi AMK Cloonan SM Autophagy and inflammation in chronic respiratory disease Autophagy 2018 14 221 232 10.1080/15548627.2017.1389823 29130366
Racanelli, A. C., Kikkers, S. A., Choi, A. M. K. & Cloonan, S. M. Autophagy and inflammation in chronic respiratory disease. Autophagy 14, 221–232 (2018).29130366 10.1080/15548627.2017.1389823
98. Ni HM Activation of autophagy protects against acetaminophen-induced hepatotoxicity Hepatology 2012 55 222 232 10.1002/hep.24690 21932416
Ni, H. M. et al. Activation of autophagy protects against acetaminophen-induced hepatotoxicity. Hepatology 55, 222–232 (2012).21932416 10.1002/hep.24690
99. Ni HM Jaeschke H Ding WX Targeting autophagy for drug-induced hepatotoxicity Autophagy 2012 8 709 710 10.4161/auto.19659 22441014
Ni, H. M., Jaeschke, H. & Ding, W. X. Targeting autophagy for drug-induced hepatotoxicity. Autophagy 8, 709–710 (2012).22441014 10.4161/auto.19659
100. Fant X cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer’s disease Mol. Pharm. 2014 85 441 450 10.1124/mol.113.090837
Fant, X. et al. cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer’s disease. Mol. Pharm. 85, 441–450 (2014).10.1124/mol.113.090837
101. Duncan PI Stojdl DF Marius RM Bell JC In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase Mol. Cell Biol. 1997 17 5996 6001 10.1128/MCB.17.10.5996 9315658
Duncan, P. I., Stojdl, D. F., Marius, R. M. & Bell, J. C. In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase. Mol. Cell Biol. 17, 5996–6001 (1997).9315658 10.1128/MCB.17.10.5996
102. Quidville V Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy Cancer Res 2013 73 2247 2258 10.1158/0008-5472.CAN-12-2501 23358685
Quidville, V. et al. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res. 73, 2247–2258 (2013).23358685 10.1158/0008-5472.CAN-12-2501
103. Margariti A XBP1 mRNA splicing triggers an autophagic response in endothelial cells through BECLIN-1 transcriptional activation J. Biol. Chem. 2013 288 859 872 10.1074/jbc.M112.412783 23184933
Margariti, A. et al. XBP1 mRNA splicing triggers an autophagic response in endothelial cells through BECLIN-1 transcriptional activation. J. Biol. Chem. 288, 859–872 (2013).23184933 10.1074/jbc.M112.412783
104. Sun QZ Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers J. Med Chem. 2017 60 6337 6352 10.1021/acs.jmedchem.7b00665 28692292
Sun, Q. Z. et al. Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers. J. Med Chem. 60, 6337–6352 (2017).28692292 10.1021/acs.jmedchem.7b00665
105. Nakamura M Sadoshima J Mechanisms of physiological and pathological cardiac hypertrophy Nat. Rev. Cardiol. 2018 15 387 407 10.1038/s41569-018-0007-y 29674714
Nakamura, M. & Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat. Rev. Cardiol. 15, 387–407 (2018).29674714 10.1038/s41569-018-0007-y
106. Kehat I Molkentin JD Molecular pathways underlying cardiac remodeling during pathophysiological stimulation Circulation 2010 122 2727 2735 10.1161/CIRCULATIONAHA.110.942268 21173361
Kehat, I. & Molkentin, J. D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122, 2727–2735 (2010).21173361 10.1161/CIRCULATIONAHA.110.942268
107. Biddinger SB Kahn CR From mice to men: insights into the insulin resistance syndromes Annu. Rev. Physiol. 2006 68 123 158 10.1146/annurev.physiol.68.040104.124723 16460269
Biddinger, S. B. & Kahn, C. R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123–158 (2006).16460269 10.1146/annurev.physiol.68.040104.124723
108. Pilkis SJ Granner DK Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis Annu. Rev. Physiol. 1992 54 885 909 10.1146/annurev.ph.54.030192.004321 1562196
Pilkis, S. J. & Granner, D. K. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu. Rev. Physiol. 54, 885–909 (1992).1562196 10.1146/annurev.ph.54.030192.004321
109. Haltenhof T A Conserved Kinase-Based Body-Temperature Sensor Globally Controls Alternative Splicing and Gene Expression Mol. Cell 2020 78 57 69 10.1016/j.molcel.2020.01.028 32059760
Haltenhof, T. et al. A Conserved Kinase-Based Body-Temperature Sensor Globally Controls Alternative Splicing and Gene Expression. Mol. Cell 78, 57–69 (2020). e54.32059760 10.1016/j.molcel.2020.01.028
110. Buhr ED Yoo SH Takahashi JS Temperature as a universal resetting cue for mammalian circadian oscillators Science 2010 330 379 385 10.1126/science.1195262 20947768
Buhr, E. D., Yoo, S. H. & Takahashi, J. S. Temperature as a universal resetting cue for mammalian circadian oscillators. Science 330, 379–385 (2010).20947768 10.1126/science.1195262
111. Naro C Sette C Phosphorylation-mediated regulation of alternative splicing in cancer Int J. Cell Biol. 2013 2013 151839 10.1155/2013/151839 24069033
Naro, C. & Sette, C. Phosphorylation-mediated regulation of alternative splicing in cancer. Int J. Cell Biol. 2013, 151839 (2013).24069033 10.1155/2013/151839
112. Corkery DP Holly AC Lahsaee S Dellaire G Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response Nucleus 2015 6 279 288 10.1080/19491034.2015.1062194 26098145
Corkery, D. P., Holly, A. C., Lahsaee, S. & Dellaire, G. Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response. Nucleus 6, 279–288 (2015).26098145 10.1080/19491034.2015.1062194
113. Wang E Aifantis I RNA Splicing and Cancer Trends Cancer 2020 6 631 644 10.1016/j.trecan.2020.04.011 32434734
Wang, E. & Aifantis, I. RNA Splicing and Cancer. Trends Cancer 6, 631–644 (2020).32434734 10.1016/j.trecan.2020.04.011
114. Kang, E. et al. Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-β pathway. Cancer Gene Ther. 29, 1168–1180(2022).
115. Blackie AC Foley DJ Exploring the roles of the Cdc2-like kinases in cancers Bioorg. Med. Chem. 2022 70 116914 10.1016/j.bmc.2022.116914 35872347
Blackie, A. C. & Foley, D. J. Exploring the roles of the Cdc2-like kinases in cancers. Bioorg. Med. Chem. 70, 116914 (2022).35872347 10.1016/j.bmc.2022.116914
116. Dominguez, D. et al. An extensive program of periodic alternative splicing linked to cell cycle progression. Elife. 5, 15 (2016).
117. Fedorov O Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing Chem. Biol. 2011 18 67 76 10.1016/j.chembiol.2010.11.009 21276940
Fedorov, O. et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem. Biol. 18, 67–76 (2011).21276940 10.1016/j.chembiol.2010.11.009
118. Naro C Bielli P Sette C Oncogenic dysregulation of pre-mRNA processing by protein kinases: challenges and therapeutic opportunities Febs j. 2021 288 6250 6272 10.1111/febs.16057 34092037
Naro, C., Bielli, P. & Sette, C. Oncogenic dysregulation of pre-mRNA processing by protein kinases: challenges and therapeutic opportunities. Febs j. 288, 6250–6272 (2021).34092037 10.1111/febs.16057
119. Uzor S CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer Sci. Rep. 2021 11 7963 10.1038/s41598-021-86908-6 33846420
Uzor, S. et al. CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Sci. Rep. 11, 7963 (2021).33846420 10.1038/s41598-021-86908-6
120. Bowler E Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells BMC Cancer 2018 18 355 10.1186/s12885-018-4227-7 29606096
Bowler, E. et al. Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells. BMC Cancer 18, 355 (2018).29606096 10.1186/s12885-018-4227-7
121. Liu B Kong X Wang R Xin C CLK2 promotes occurrence and development of non-small cell lung cancer J. buon 2021 26 58 64 33721432
Liu, B., Kong, X., Wang, R. & Xin, C. CLK2 promotes occurrence and development of non-small cell lung cancer. J. buon 26, 58–64 (2021).33721432
122. Iwai, K. et al. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Mol Med. 10, e8289 (2018).
123. Park SY Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma Oncotarget 2016 7 26793 26805 10.18632/oncotarget.8471 27050366
Park, S. Y. et al. Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget 7, 26793–26805 (2016).27050366 10.18632/oncotarget.8471
124. Zhou, Q. et al. Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism. J. Exp. Med. 217, e20191779 (2020).
125. Li H CLK3 Is A Direct Target Of miR-144 And Contributes To Aggressive Progression In Hepatocellular Carcinoma Onco Targets Ther. 2019 12 9201 9213 10.2147/OTT.S224527 31807004
Li, H. et al. CLK3 Is A Direct Target Of miR-144 And Contributes To Aggressive Progression In Hepatocellular Carcinoma. Onco Targets Ther. 12, 9201–9213 (2019).31807004 10.2147/OTT.S224527
126. Shen Y Methionine oxidation of CLK4 promotes the metabolic switch and redox homeostasis in esophageal carcinoma via inhibiting MITF selective autophagy Clin. Transl. Med 2022 12 e719 10.1002/ctm2.719 35092699
Shen, Y. et al. Methionine oxidation of CLK4 promotes the metabolic switch and redox homeostasis in esophageal carcinoma via inhibiting MITF selective autophagy. Clin. Transl. Med. 12, e719 (2022).35092699 10.1002/ctm2.719
127. Tam BY The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models Cancer Lett. 2020 473 186 197 10.1016/j.canlet.2019.09.009 31560935
Tam, B. Y. et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 473, 186–197 (2020).31560935 10.1016/j.canlet.2019.09.009
128. Muraki M Manipulation of alternative splicing by a newly developed inhibitor of Clks J. Biol. Chem. 2004 279 24246 24254 10.1074/jbc.M314298200 15010457
Muraki, M. et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem. 279, 24246–24254 (2004).15010457 10.1074/jbc.M314298200
129. Brahmaiah D Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase Bioorg. Med. Chem. 2021 31 115962 10.1016/j.bmc.2020.115962 33422908
Brahmaiah, D. et al. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase. Bioorg. Med. Chem. 31, 115962 (2021).33422908 10.1016/j.bmc.2020.115962
130. Grabher P Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts Planta Med 2012 78 951 956 10.1055/s-0031-1298625 22673832
Grabher, P. et al. Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts. Planta Med. 78, 951–956 (2012).22673832 10.1055/s-0031-1298625
131. Funnell T CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor Nat. Commun. 2017 8 7 10.1038/s41467-016-0008-7 28232751
Funnell, T. et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor. Nat. Commun. 8, 7 (2017).28232751 10.1038/s41467-016-0008-7
132. Murai A Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors PLoS One 2020 15 e0240718 10.1371/journal.pone.0240718 33064779
Murai, A. et al. Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors. PLoS One 15, e0240718 (2020).33064779 10.1371/journal.pone.0240718
133. Araki S Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing PLoS One 2015 10 e0116929 10.1371/journal.pone.0116929 25581376
Araki, S. et al. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS One 10, e0116929 (2015).25581376 10.1371/journal.pone.0116929
134. Němec V Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core Eur. J. Med. Chem. 2021 215 113299 10.1016/j.ejmech.2021.113299 33636538
Němec, V. et al. Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. Eur. J. Med. Chem. 215, 113299 (2021).33636538 10.1016/j.ejmech.2021.113299
135. Walter A Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype PLoS One 2018 13 e0196761 10.1371/journal.pone.0196761 29723265
Walter, A. et al. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype. PLoS One 13, e0196761 (2018).29723265 10.1371/journal.pone.0196761
136. Kim H Identification of a novel function of CX-4945 as a splicing regulator PLoS One 2014 9 e94978 10.1371/journal.pone.0094978 24743259
Kim, H. et al. Identification of a novel function of CX-4945 as a splicing regulator. PLoS One 9, e94978 (2014).24743259 10.1371/journal.pone.0094978
137. Lertsuwan, J. et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers (Basel). 10, 113 (2018).
138. Kim J Hwan Kim S CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells PLoS One 2013 8 e74342 10.1371/journal.pone.0074342 24023938
Kim, J. & Hwan Kim, S. CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells. PLoS One 8, e74342 (2013).24023938 10.1371/journal.pone.0074342
139. Siddiqui-Jain A CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy Cancer Res 2010 70 10288 10298 10.1158/0008-5472.CAN-10-1893 21159648
Siddiqui-Jain, A. et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70, 10288–10298 (2010).21159648 10.1158/0008-5472.CAN-10-1893
140. Buontempo F Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB Oncotarget 2016 7 1323 1340 10.18632/oncotarget.6361 26593250
Buontempo, F. et al. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget 7, 1323–1340 (2016).26593250 10.18632/oncotarget.6361
141. Manni S Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells PLoS One 2013 8 e75280 10.1371/journal.pone.0075280 24086494
Manni, S. et al. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS One 8, e75280 (2013).24086494 10.1371/journal.pone.0075280
142. Pathak HB A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer PLoS One 2015 10 e0144126 10.1371/journal.pone.0144126 26637171
Pathak, H. B. et al. A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer. PLoS One 10, e0144126 (2015).26637171 10.1371/journal.pone.0144126
143. Zakharia K Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma Transl. Oncol. 2019 12 143 153 10.1016/j.tranon.2018.09.005 30316146
Zakharia, K. et al. Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. Transl. Oncol. 12, 143–153 (2019).30316146 10.1016/j.tranon.2018.09.005
144. D’Amore C Borgo C Sarno S Salvi M Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance Cell Oncol. (Dordr.) 2020 43 1003 1016 10.1007/s13402-020-00566-w 33052585
D’Amore, C., Borgo, C., Sarno, S. & Salvi, M. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance. Cell Oncol. (Dordr.) 43, 1003–1016 (2020).33052585 10.1007/s13402-020-00566-w
145. Nitta RT Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide Oncogene 2019 38 6867 6879 10.1038/s41388-019-0927-y 31406250
Nitta, R. T. et al. Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide. Oncogene 38, 6867–6879 (2019).31406250 10.1038/s41388-019-0927-y
146. Riggs JR The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen J. Med. Chem. 2017 60 8989 9002 10.1021/acs.jmedchem.7b01223 28991472
Riggs, J. R. et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J. Med. Chem. 60, 8989–9002 (2017).28991472 10.1021/acs.jmedchem.7b01223
147. Schmitt C Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors PLoS One 2014 9 e87851 10.1371/journal.pone.0087851 24676346
Schmitt, C. et al. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors. PLoS One 9, e87851 (2014).24676346 10.1371/journal.pone.0087851
148. Tahtouh T Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B J. Med. Chem. 2012 55 9312 9330 10.1021/jm301034u 22998443
Tahtouh, T. et al. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J. Med. Chem. 55, 9312–9330 (2012).22998443 10.1021/jm301034u
149. Loaëc, N. et al. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases. Mar. Drugs. 15, 316 (2017).
150. Debdab M Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing J. Med. Chem. 2011 54 4172 4186 10.1021/jm200274d 21615147
Debdab, M. et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J. Med. Chem. 54, 4172–4186 (2011).21615147 10.1021/jm200274d
151. Prak K Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members Biochemistry 2016 55 608 617 10.1021/acs.biochem.5b01128 26701387
Prak, K. et al. Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members. Biochemistry 55, 608–617 (2016).26701387 10.1021/acs.biochem.5b01128
152. Coombs TC Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315 Bioorg. Med. Chem. Lett. 2013 23 3654 3661 10.1016/j.bmcl.2013.02.096 23642479
Coombs, T. C. et al. Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg. Med. Chem. Lett. 23, 3654–3661 (2013).23642479 10.1016/j.bmcl.2013.02.096
153. Shi Y A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore Bioorg. Med. Chem. Lett. 2017 27 406 412 10.1016/j.bmcl.2016.12.056 28049589
Shi, Y. et al. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg. Med. Chem. Lett. 27, 406–412 (2017).28049589 10.1016/j.bmcl.2016.12.056
154. Rosenthal, A. S. et al. in Probe Reports from the NIH Molecular Libraries Program (National Center for Biotechnology Information (US), 2010).
155. Rosenthal AS Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk) Bioorg. Med. Chem. Lett. 2011 21 3152 3158 10.1016/j.bmcl.2011.02.114 21450467
Rosenthal, A. S. et al. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg. Med. Chem. Lett. 21, 3152–3158 (2011).21450467 10.1016/j.bmcl.2011.02.114
156. Murár M Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands Eur. J. Med. Chem. 2017 126 754 761 10.1016/j.ejmech.2016.11.003 27940419
Murár, M. et al. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands. Eur. J. Med. Chem. 126, 754–761 (2017).27940419 10.1016/j.ejmech.2016.11.003
157. Fruman DA The PI3K Pathway in Human Disease Cell 2017 170 605 635 10.1016/j.cell.2017.07.029 28802037
Fruman, D. A. et al. The PI3K Pathway in Human Disease. Cell 170, 605–635 (2017).28802037 10.1016/j.cell.2017.07.029
158. Du R Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy Mol. Cancer 2021 20 15 10.1186/s12943-020-01305-3 33451333
Du, R. et al. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Mol. Cancer 20, 15 (2021).33451333 10.1186/s12943-020-01305-3
159. Song M Bode AM Dong Z Lee MH AKT as a Therapeutic Target for Cancer Cancer Res 2019 79 1019 1031 10.1158/0008-5472.CAN-18-2738 30808672
Song, M., Bode, A. M., Dong, Z. & Lee, M. H. AKT as a Therapeutic Target for Cancer. Cancer Res. 79, 1019–1031 (2019).30808672 10.1158/0008-5472.CAN-18-2738
160. Liu H Liu K Dong Z Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery Cancer Res 2021 81 18 26 10.1158/0008-5472.CAN-20-2245 32958547
Liu, H., Liu, K. & Dong, Z. Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery. Cancer Res. 81, 18–26 (2021).32958547 10.1158/0008-5472.CAN-20-2245
161. Huang C CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating β-catenin/ MEK-ERK signaling pathway Cell Death Differ. 2022 29 14 27 10.1038/s41418-021-00828-6 34262144
Huang, C. et al. CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating β-catenin/ MEK-ERK signaling pathway. Cell Death Differ. 29, 14–27 (2022).34262144 10.1038/s41418-021-00828-6
162. Lee MH Kundu JK Chae JI Shim JH Targeting ROCK/LIMK/cofilin signaling pathway in cancer Arch. Pharm. Res. 2019 42 481 491 10.1007/s12272-019-01153-w 31030376
Lee, M. H., Kundu, J. K., Chae, J. I. & Shim, J. H. Targeting ROCK/LIMK/cofilin signaling pathway in cancer. Arch. Pharm. Res. 42, 481–491 (2019).31030376 10.1007/s12272-019-01153-w
163. Lindberg, M. F. & Meijer, L. Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. Int. J. Mol Sci. 22, 6047 (2021).
164. Carling D AMPK signalling in health and disease Curr. Opin. Cell Biol. 2017 45 31 37 10.1016/j.ceb.2017.01.005 28232179
Carling, D. AMPK signalling in health and disease. Curr. Opin. Cell Biol. 45, 31–37 (2017).28232179 10.1016/j.ceb.2017.01.005
165. Johnson GL Lapadat R Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases Science 2002 298 1911 1912 10.1126/science.1072682 12471242
Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911–1912 (2002).12471242 10.1126/science.1072682
166. George A Aubol BE Fattet L Adams JA Disordered protein interactions for an ordered cellular transition: Cdc2-like kinase 1 is transported to the nucleus via its Ser-Arg protein substrate J. Biol. Chem. 2019 294 9631 9641 10.1074/jbc.RA119.008463 31064840
George, A., Aubol, B. E., Fattet, L. & Adams, J. A. Disordered protein interactions for an ordered cellular transition: Cdc2-like kinase 1 is transported to the nucleus via its Ser-Arg protein substrate. J. Biol. Chem. 294, 9631–9641 (2019).31064840 10.1074/jbc.RA119.008463
167. Grosso AR Martins S Carmo-Fonseca M The emerging role of splicing factors in cancer EMBO Rep. 2008 9 1087 1093 10.1038/embor.2008.189 18846105
Grosso, A. R., Martins, S. & Carmo-Fonseca, M. The emerging role of splicing factors in cancer. EMBO Rep. 9, 1087–1093 (2008).18846105 10.1038/embor.2008.189
168. Srebrow A Kornblihtt AR The connection between splicing and cancer J. Cell Sci. 2006 119 2635 2641 10.1242/jcs.03053 16787944
Srebrow, A. & Kornblihtt, A. R. The connection between splicing and cancer. J. Cell Sci. 119, 2635–2641 (2006).16787944 10.1242/jcs.03053
169. Urbanski LM Leclair N Anczuków O Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics Wiley Interdiscip. Rev. RNA 2018 9 e1476 10.1002/wrna.1476 29693319
Urbanski, L. M., Leclair, N. & Anczuków, O. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip. Rev. RNA 9, e1476 (2018).29693319 10.1002/wrna.1476
170. Aird D Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators Nat. Commun. 2019 10 137 10.1038/s41467-018-08150-5 30635584
Aird, D. et al. Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators. Nat. Commun. 10, 137 (2019).30635584 10.1038/s41467-018-08150-5
171. Al-Tawil MF Daoud S Hatmal MM Taha MO Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning RSC Adv. 2022 12 10686 10700 10.1039/D2RA00136E 35424985
Al-Tawil, M. F., Daoud, S., Hatmal, M. M. & Taha, M. O. Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning. RSC Adv. 12, 10686–10700 (2022).35424985 10.1039/D2RA00136E
172. Mazanetz MP Goode CHF Chudyk EI Ligand- and Structure-Based Drug Design and Optimization using KNIME Curr. Med. Chem. 2020 27 6458 6479 10.2174/0929867326666190409141016 30963962
Mazanetz, M. P., Goode, C. H. F. & Chudyk, E. I. Ligand- and Structure-Based Drug Design and Optimization using KNIME. Curr. Med. Chem. 27, 6458–6479 (2020).30963962 10.2174/0929867326666190409141016
173. Śledź P Caflisch A Protein structure-based drug design: from docking to molecular dynamics Curr. Opin. Struct. Biol. 2018 48 93 102 10.1016/j.sbi.2017.10.010 29149726
Śledź, P. & Caflisch, A. Protein structure-based drug design: from docking to molecular dynamics. Curr. Opin. Struct. Biol. 48, 93–102 (2018).29149726 10.1016/j.sbi.2017.10.010
